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ABSTRACT 
In human end-stage heart failure patients, the activation of Rho kinase 1 (ROCK1) is 
observed in the heart. ROCK1 activation promotes the activation of caspase 3, which 
results in a feed-forward loop contributing to myocyte apoptosis. Rnd3, a small GTPase, 
is an endogenous inhibitor of ROCK1. I observed a decrease in Rnd3 protein levels in 
human failing hearts, suggesting a pathological significance of Rnd3 alteration in the 
transition to heart failure. However, the biological function of Rnd3 in the heart remains 
unexplored. To investigate the functional role of Rnd3 in the heart and the underlying 
mechanism, the Rnd3 knockout mouse line was generated to mimic the down-regulation 
of Rnd3 in the diseased human heart. Rnd3 deficiency (Rnd3
-/-
) resulted in embryonic
lethality. Severe cardiac apoptosis along with elevated ROCK1 activity were observed in 
the Rnd3
-/- 
mice at the E10.5 stage. The haploinsufficient (Rnd3
+/-
) mice were viable,
however, were predisposed to heart failure after transverse aortic constriction (TAC) 
induced hemodynamic stress. Remarkable cardiomyocyte apoptosis, increased caspase 3 
activity, and activation of ROCK1 were detected in the Rnd3
+/- 
heart compared to the
wild-type (WT) control. Pharmacological inhibition of ROCK1 by Fasudil 
administration partially improved cardiac function and attenuated apoptosis in the 
Rnd3
+/- 
mice after TAC. To determine whether ROCK1 contributed to the Rnd3
deficiency-mediated heart failure and cardiac apoptosis, I generated a double knockout 
(DKO) mouse line with Rnd3
+/- ROCK1-/- 
background. Again, the genetic deletion of
ROCK1 partially rescued the phenotype. My data suggest that Rnd3 is a novel anti-
iii 
apoptotic factor that protects the heart from cardiac apoptosis partially through the 
inhibition of the ROCK1 pathway. 
Determining the ROCK1 independent mechanisms involved in the Rnd3 deficiency-
mediated cardiac remodeling is the goal for further investigation. Compensatory 
angiogenesis is necessary in the cardiac response to the ischemic stimuli. Compared to 
the wild-type mice, the post-TAC Rnd3
+/-
 hearts showed significantly smaller capillary
areas, fewer capillary numbers, a 20.8% reduction of coronary flow reserve, and a 5.9-
fold increase in the hypoxic myocardial areas. Key pro-angiogenic factors were down-
regulated, including hypoxia-inducible factor 1α (HIF1α) and vascular endothelial 
growth factor A (VEGFA), suggesting a stress-responsive angiogenic defect. Using loss- 
and gain-of-function approaches, I revealed that Rnd3 physically interacted with and 
stabilized HIF1α. The deficiency of Rnd3 facilitated the HIF1α protein degradation, 
reduced the VEGFA expression, and compromised the endothelial cell tube formation. 
Finally, the angiogenesis defect and the heart failure phenotype in the Rnd3
+/-
 mice were
partially rescued by cobalt chloride treatment, a HIF1α stabilizer. My data suggests that 
Rnd3 is a pro-angiogenic factor involved in the responsive angiogenesis in the heart 
through HIF1α-VEGF signaling promotion. Animals with Rnd3 haploinsufficiency 
showed cardiac dysfunction with impaired angiogenesis in response to the pressure 
overload. The down-regulation of Rnd3 observed in the heart failure patients may 
explain the insufficiency in the compensatory angiogenesis, which contributes to the 
transition to heart failure. 
iv 
 
DEDICATION 
 
 
I dedicate this dissertation to my family, my mentor, and all of my friends.  
Especially to my father and mother for instilling the importance of hard work and higher 
education; 
To my grandfather and grandmother for the encouragement; 
To Dr. Jiang Chang for his guidance and care; 
To Xiangsheng Yang and Xi Lin for their friendship and kind help; 
To Guangyu, may you achieve your dreams. 
 
 
 
 
 
 
 
 
v 
 
ACKNOWLEDGEMENTS 
 
 
This work has been carried out at the Texas A&M University Health Science Center 
Institute of Bioscience and Technology under the guidance of Dr. Jiang Chang during 
the years 2010-2015. Support for this research was provided by Grants: the American 
Heart Association Grant-in-Aid 0855030F, the NIH-NHLBI R01HL102314, the NIH-
NHLBI R01HL123953, and the NIH-K02HL098956 to Jiang Chang; the American 
Heart Association Postdoctoral Fellowship 13POST17260043 to Xiangsheng Yang; the 
China Scholarship Council Fellowship to Xiaojing Yue; the National Natural Science 
Foundation of China 81460070 to Tianfa Li, 1160020 and 81460042 to Junli Guo.  
 
First of all, I would like to express my sincere gratitude from the deepest part of my 
heart to my mentor, Dr. Jiang Chang, for offering me a precious opportunity to join his 
group; for his mentoring during the this five-year study; for his encouragement 
whenever there were rainy days; for his inspiration whenever there was confusion.  Dr. 
Chang is more than just a mentor in the lab. He encouraged me while attending scientific 
conferences to explore the most advanced research progressions. He is also a great 
supervisor that guided me in public presentation, research paper writing, and early career 
development. I am so lucky to have him as my graduate advisor. Secondly, let me 
express my sincere thanks to my graduate advisor committee members. Dr. Jianming Xu 
inspires me with his millions of questions. Dr. Dekai Zhang encourages me. Dr. Xia Lin 
treats me as her own child. I still remember her gentle words of comfort when I sprained 
vi 
 
my ankle a few months ago. Without their time, comments, and support, I could never 
make it today. Thirdly, all members in Dr. Chang’s group, their friendship and kindness 
really mean a lot to me. Dr. Xiangsheng Yang, also my fiancé, encouraged me to 
overcome my shyness and to become an independent strong woman. Dr. Xi Lin, one of 
my best friends, always helped us to move our work forward and took care of us in our 
life. Kelsey Andrade, our manager, provided me suggestions for my paper writing and 
deals with everything that happens in the lab. The graduate students Yuan Dai, Tingli 
Yang, Jian Yang, Ming Wang, and Xin Yi; we worked as a team and accomplished the 
projects together. I also want to thank the past members, Baohui Liu, Huimin Dong, 
Junli Guo, Ping Gao and Wei Jie for their friendship and support. 
 
Last but not the least, I would thank the Texas A&M University Health Science Center 
Institute of Bioscience and Technology where I studied and lived for the past five years. 
All of the people, the animal facility, HR, administrators, physical plant, security; all 
together, we make the IBT a better place for research as well as for life. I will cherish 
those precious memories we have together. Thank you all. 
 
 
 
 
 
 
vii 
NOMENCLATURE 
Rnd3 Rho family small GTPase3 
ROCK Rho-associated coiled-coil protein kinase 
CVDs Cardiovascular diseases 
TAC Transverse aortic constriction 
HCM Hypertrophic cardiomyopathy 
DCM Dilated cardiomyopathy 
RCM Restrictive cardiomyopathy 
ARVC Arrhythmogenic right ventricular cardiomyopathy 
IVS Interventricular septum thickness 
LVID Left ventricle inner dimension 
LVPW Left ventricle posterior wall thickness  
EF Ejection fraction 
FS Fractional shortening 
LW Lung weight 
BW Body weight 
TL Tibia length 
Casp3 Caspase 3 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
MYPT1 Myosin phosphatase target subunit 1 
MLC2 Myosin light chain 2 
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DKO  Double-knockout 
VEGF  Vascular endothelial growth factor 
HIF1α  Hypoxia-inducible factor 1 α subunit 
HRE  Hypoxia responsive element 
PHD  Prolyl hydroxylase 
HUVECs Human umbilical vein endothelial cells 
CFR  Coronary flow reserve 
UPS  Ubiquitin-proteasome system 
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CHAPTER I 
INTRODUCTION 
Cardiovascular Diseases (CVDs) 
Cardiovascular diseases (CVDs) including hypertension (high blood pressure, HBP), 
coronary heart disease, stroke and heart failure have been the biggest threats to the health 
of Americans. According to the newest data of mortalities statistically summarized by 
the American Heart Association, CVDs accounted for 31.9% of all deaths in the United 
States in 2010
1, 2
. Also in 2010, 77.9 million US adults (33% of the entire population)
were estimated to have hypertension and the mortality of this disease was 18.8%. 
Around 15.4 million US adults have coronary heart diseases including heart attack, chest 
pain, heart failure, stroke and congenital cardiovascular defects. The estimated total cost 
of treatment for CVDs in 2010 was $315.4 billion. Compared to the estimated $201.5 
billion treatment cost of all cancers and benign neoplasms in 2008, CVDs cost much 
more than any other disease group
1
.
Many mechanisms contribute to the development of CVDs. Heart remodeling, vascular 
remodeling, cardiac cell apoptosis, reactive oxygen species overproduction, energy 
generation/demand imbalance and disturbed calcium homeostasis could all result in 
cardiac and vascular dysfunction as well as morphology remodeling. Our lab has been 
focusing on chronic stimuli caused heart failure in adults and its pathogenesis in 
response to hemodynamic stress. 
2 
Classification of Cardiomyopathies 
A cardiomyopathy is characterized as heart muscle disease with an impaired contractile 
ability or an irregular heartbeat. The prior classification of cardiomyopathies was 
defined by the 1995 World Health Organization/ International Society and Federation of 
Cardiology Task Force (WHO/ISFC). It simply identified hypertrophic cardiomyopathy 
(HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), 
arrhythmogenic right ventricular cardiomyopathy (ARVC) and specific cardiomyopathy 
(unclassified), which made the classification controversial and confusing by mixing the 
anatomic definition with functional ones
3
. However, it was helpful in understanding the
distinctions between the complex diseases. The European Society of Cardiology further 
made a contemporary classification determined by morphological and functional 
phenotypes. Based on the cardiomyopathies (HCM, DCM, RCM, ARVC and 
unclassified cardiomyopathies) defined by the 1995 WHO/ISFC, each cardiomyopathy 
was further divided into the genetic group and the non-genetic group according to if the 
cardiomyopathy is caused by genetic polymorphism or not
4
. Debatably, the American
Heart Association provided a more complicated classification method depending on the 
predominant organ involvement and divided the cardiomyopathies into two major 
categories: primary cardiomyopathies and secondary cardiomyopathies
5
. The primary
cardiomyopathies are predominantly confined to heart muscle. They are further divided 
into genetic, non-genetic and acquired groups. For example, HCM and ARVC/D belong 
to the genetic group since disease-causing gene mutations are associated in all HCM and 
ARVC/D patients; while DCM belongs to the genetic/non-genetic mix group. DNA 
3 
 
sequencing became an effective tool in systemically predicting genetic cardiomyopathies. 
The secondary cardiomyopathies are caused by other pathological factors not 
predominantly in heart, such as toxicity, inflammation, autoimmune, endocrine and 
consequences of cancer therapy. Same as the primary category, the secondary 
cardiomyopathies also can emerge from genetic and non-genetic origins
5
. 
 
Hypertrophic Cardiomyopathy (HCM) 
Hypertrophic cardiomyopathy (HCM) is an inherited pathological myocardium with 
hypertrophic remodeling mainly happening in the left ventricle posterior wall, and in 
certain cases, in the apex, septum, and right ventricle, resulting in an increase in the wall 
thickness. Patients diagnosed with HCM develop abnormal left ventricular wall 
thickness ranging widely from 13 to 50 mm
6, 7, 8
, and probably in the presence of 
diastolic dysfunction and other morphological abnormalities such as microvascular 
disorders, cardiac fibrosis and mitral-valve enlargement or elongation. ECG 
measurement followed by image detection, including 2-D echocardiography and cardiac 
MRI analysis, are used for clinical diagnosis. Symmetrical left ventricular hypertrophy is 
rarely observed, while approximately 50% of patients develop asymmetrical HCM with 
diffuse left ventricle wall thickening
8
.   
 
HCM is a genetic cardiac disease normally associated with the mutation of genes 
encoding the component proteins of sarcomeres. More than 1600 predominant mutations 
of 11 genes were identified in the HCM-inherited patients in past decades. The identified 
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genes encode the proteins that compose the contractile unit of the myofilament or z-disc, 
such as α-myosin heavy chain, β-myosin heavy chain, troponin T, myosin-binding 
protein C, vinculin and junctophilin2, and the regulator of myosin such as Rho kinase
8
.  
However, people with these gene mutations probably do not display a left ventricular 
hypertrophic phenotype at a young age, but the symptoms might be recognized at 
adulthood or even at an older age
9
. Therefore, the age-related hypertrophic phenotype 
development makes the disease difficult to diagnose at an early stage based on the 
imaging system, while the DNA-based analysis largely facilitates early diagnosis for 
patients at risk of genetic HCM.  
 
Dilated Cardiomyopathy (DCM) 
Dilated cardiomyopathy (DCM) is the heart muscle disease characterized by systolic 
dysfunction, enlargement of the ventricular chamber and either a normal or thin 
ventricular wall along with myocyte hypertrophy or elongation. The symptom of DCM 
can be identified by ECG and 2-D echocardiography, and might be confirmed by an 
endomyocardial biopsy and coronary angiography. The DNA-based test also facilitates 
the diagnosis of the genetic defect that causes DCM. Determined by 2-D 
echocardiography measurement, two important clinical criteria for DCM diagnosis are a 
117% or more increase in the left ventricular end diastolic dimension (LVEDD) value 
and a value of the fractional shortening (FS) less than 25%
10
. In certain cases DCM is 
diagnosed in the presence of arrhythmias, fibrosis, dynamic obstruction or heart failure.  
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25%-35% of DCM patients are diagnosed with familial DCM caused by gene mutations, 
and the remaining patients have the secondary DCM caused by other diseases or 
conditions
10
. The mutation of the genes encoding the myofilament component protein, 
the skeleton-plasma membrane network component protein and the calcium channel 
result in primary DCM, which is a genetic disease and could be inherited by family 
members. The secondary DCM could be induced by ischemic heart disease, coronary 
artery disease, hypertension, myocarditis, diabetes, excessive alcohol intake, etc. Our lab 
has successfully generated the mouse DCM model by the transverse aortic constriction 
(TAC) technique. Under hemodynamic stress conditions, the mouse heart developed 
DCM with diastolic and systolic dysfunction, cardiomyocyte apoptosis and capillary 
rarefaction. This animal model specifically recapitulates the clinical pathological DCM 
remodeling during the transition of the heart to failure, and is suitable for the 
mechanistic investigation of DCM etiology. 
 
Rho-associated Coiled-coil Kinase (ROCK) in Physiology and Pathology 
Rho-associated coiled-coil kinase (ROCK) was first identified from bovine brain in 1996, 
and was also named Rho kinase because of its characteristic interaction with GTPγs, 
RhoA, RhoB and RhoC
11, 12, 13
. As a major downstream effector of RhoA, ROCK is 
involved in the functions of the Rho family including appropriate responses of 
extracellular signals, stimulated cytoskeleton dynamics and focal adhesion formation. 
The two members of the human ROCK family, ROCK1 (ROKβ or p160ROCK) and 
ROCK2 (ROKα), share 60.9% nucleotide sequence homology and a particularly high 
6 
homology of 92% in kinase domains
14
, suggesting potential complementary functions
between the two isoforms. Both ROCKs are composed of an N-terminal functional 
kinase domain, a coiled-coil forming region containing Rho-binding domain, a 
pleckstrin homology (PH) domain and a C-terminal cysteine-rich zinc finger
14
.
The ROCK family belongs to the classical serine/threonine kinases PKA, PKG and PKC 
family
15
 and directly or indirectly phosphorylates several downstream targets resulting in
the regulation of cytoskeleton dynamics and stress fiber contractility. Myosin light chain 
(MLC) is one of the substrates phosphorylated by ROCK. The MLC is activated by 
phosphorylation and directly results in smooth muscle contraction via the facilitation of 
myosin ATPase
16
. The MLC phosphorylation level is also increased by the inhibition of
myosin phosphatase through the phosphorylation modification on its myosin-binding 
subunit (MBS) by ROCK
17, 18
. ROCK also regulates the formation of stress fibers, focal
adhesions and membrane blebs by phosphorylation of LIM-kinase 1 (LIMK1) at 
threonine 508
19, 20
 and LIM-kinase 2 (LIMK 2) at threonine 505
21, 22
. The therefore
activated LIMKs phosphorylate and consequently inhibit Cofilin activity which 
suppresses actin depolymerization and facilitates actin reorganization and stabilization. 
ROCK also phosphorylates the membrane skeletal proteins Adducin and 
Ezrin/Radixin/Moesin (ERM) and therefore facilitates the assembly of actin meshwork 
interaction with the plasma membrane
23, 24
. The ROCK/MLC pathway and 
ROCK/LIMK/Cofilin pathway-mediated actin-myosin system not only regulate cellular 
adhesion, motility, morphology and intracellular transportation, but also play a 
7 
regulatory role in smooth muscle cell calcium sensitivity
25
 and the apoptotic cell
membrane blebbing process
26
.
Due to the important roles of ROCK in cytoskeleton-dependent cellular processes, 
ROCK was found as a key factor in oncogenesis. ROCK has been implicated in 
proliferation, invasion and metastatic growth of multiple cancer cells
27, 28
.
ROCK, a Key Modulator in Cardiovascular Diseases 
ROCK inhibitors Fasudil and Y-27632 were developed for the research of ROCK’s 
function in diseases and the therapeutic effects. Both two chemicals target the ATP-
dependent kinase domain of ROCK, and therefore have potential non-selective effects 
on other kinases such as PKA and PKC at high concentrations
15
. Fasudil is the only
currently approved ROCK inhibitor for human use, which has been applied on the 
clinical treatment of cerebral vasospasm in Japan. The ROCK inhibitors were used in 
multiple animal models in vivo and cell experiments in vitro to study the functions of 
ROCK and the underlining mechanisms in cardiovascular diseases. 
The effects of ROCK on vascular smooth muscle cells have been extensively studied. 
ROCK promotes smooth muscle cell contraction
29
, migration
30
 and proliferation
31, 32
,
which contribute to hypertension development. Activation of ROCK has been detected 
in many hypertension animal models and hypertensive patients. Application of Fasudil 
in spontaneously hypertensive rats (SHR) effectively suppressed smooth muscle cell 
8 
contraction and calcium sensitivity mediated high blood pressure, meanwhile 
hypertensive blood vessel lesion formation, vascular hypertrophy and fibrosis were 
reduced with long-term Fasudil treatment
33
. Fasudil induced the activation of MLC
phosphatase (MYPT1) and the decrease in MLC phosphorylation levels suppress the 
mean arterial blood pressure in the SHR mouse model
33, 34
.
ROCK has been implicated in the regulation of endothelial cell migration and 
endothelial monolayer permeability
35, 36, 37
. Stimulated by vascular endothelial growth
factor (VEGF) and shear stress, the RhoA/ROCK pathway is activated and promotes 
endothelial cell migration and angiogenesis
35, 38
. The anti-cancer drug vinca alkaloids
can lead to pulmonary edema in breast cancer patients due to endothelial barrier 
dysfunction
39
. The phosphorylation of MYPT1 and LIMK by ROCK results in
microtubule destabilization in endothelial cells and was suggested as the mechanism
36, 37
.
Furthermore, ROCK induces the decrease of eNOS and phosphorylated eNOS levels, 
and therefore results in reduced NO production and endothelial dysfunction
34
.
Atherosclerosis is characterized by endothelial hyper-permeability, inflammatory cell 
recruitment and lipoprotein accumulation which can be mediated by ROCK signaling. 
Haploinsufficient ROCK1
+/- 
mice underwent carotid artery ligation induced vascular
injury, and developed reduced neointima formation and bone marrow-derived leukocyte 
infiltration compared with that of WT or ROCK2
+/- 
mice, indicating that ROCK1 plays
an essential role in inflammatory atherosclerosis plaque development
40
. Studies also
9 
showed that ROCK regulated the early development of atherosclerosis via NF-κB 
activation and T lymphocyte accumulation
41
.
ROCK pathway activation was observed in multiple cardiac hypertrophy and ventricular 
remodeling animal models as well as in heart failure patients. Our lab previously 
reported that after one week of hemodynamic stress exposure ROCK1
-/- 
mouse
myocardium displayed a significantly reduced number of apoptotic cardiomyocytes 
compared with that of WT mice. ROCK1 can be cleaved and consequently activated by 
caspase 3, meanwhile the truncated ROCK1 facilitates caspase 3 activation which forms 
a feed-back regulatory loop to promote apoptosis
42
. The transgenic mouse line
overexpressing truncated ROCKΔ1, which is the constitutively active form of ROCK1, 
was generated by our group.  By infusion of angiotensin-II, the ROCKΔ1 transgenic 
mice developed severe fibrotic cardiacmyopathy associated with cardiac dysfunction. In 
the ROCKΔ1 heart, ROCK1 positively modulated the TGFβ1 and NF-κB pathway in a 
serum response factor (SRF)-dependent manner, which is responsible for the 
differentiation of cardiac fibroblasts into myofibroblasts
43
.
Endogenous Regulators of ROCK 
The Rho-binding domain and PH domain located at the C-terminal of ROCK is a 
negative regulatory region leading to conformational autoinhibition. The cleavage of the 
ROCK1 C-terminal by caspase 3 in apoptosis generates a constitutively active form, 
while this process is not present in ROCK2
26, 44
. Binding of the Rho family, including
10 
RhoA, RhoB and RhoC, to the Rho-binding domain of ROCK can also release the 
catalytic kinase domain and stimulate ATP-dependent kinase activity. As a negative 
regulator, small GTPase Rnd3 (RhoE) binds to a region encompassing the kinase domain 
of ROCK1, leading to the inhibition of ROCK1 and the conformational competition with 
the binding of RhoA to ROCK1 although there is a distance between the two binding 
sites
45, 46, 47
. PDK1 competes with Rnd3 for binding to ROCK1 resulting in ROCK1
translocation to the plasma membrane and reduced kinase activity
48
. Considering the
multiple regulatory roles of ROCK1 in cardiovascular diseases, I focused on the study of 
its inhibitor, Rnd3, and its function in the heart. 
ROCK 1 Endogenous Inhibitor: Rnd3 in Physiology and Pathology 
The Rho family proteins belong to the Ras superfamily of GTPases. Best characterized 
Rho family proteins include Rho, Rac and Cdc42.  Recently, study of the Rnd subfamily, 
Rnd1, Rnd2, Rnd3/RhoE, which are expressed widely across vertebrates, is becoming 
interesting. Rnd3 is the first identified member of the Rnd subfamily, discovered by 
Jeffrey Settleman’s lab while studying its ability to interact with p190RhoGAP49. Unlike
the well characterized small GTPase, such as RhoA, Rnd3 binds to GTP but lacks 
intrinsic GTPase activity and is resistant to Rho-specific GTPase-activating proteins. 
Rnd3 expression is regulated by many different stimuli. DNA damage caused by 
chemotherapeutic agents or UV irradiation up-regulated Rnd3 expression in both mRNA 
and protein levels. The response to chemotherapeutic agents is believed to be associated 
11 
 
with p53
46, 50
, while the UV-mediated up-regulation of Rnd3 in keratinocytes is 
independent of p53
51
. Other regulators have been shown to be involved in the regulation 
of Rnd3 expression in cancers. Rnd3 expression is related to NF-κB activity in prostate 
cancer
52
;  the mTOR pathway is closely associated with Rnd3 expression in 
subependymal giant cells in brain tumors
53
.  Moreover, microRNA may regulate Rnd3 
expression.  Rnd3 was identified as a potential miR-200c target gene by using the 
informatics and q-PCR method
54
.  At the posttranslational level, Rnd3 can be stabilized 
by ROCK1&PKC phosphorylation
55, 56
. Recently one study showed that Rnd3 can 
physically interact with 14-3-3 to regulate its membrane localization, which provides a 
new mechanism for the investigation of Rnd3 regulation
57
.  
 
Biological function of Rnd3 has been studied in cultured cell lines predominantly. Rnd3 
decreases actomyosin contractility, and induces loss of stress fibers in vitro
58
. In smooth 
muscle cells, the Rnd3-mediated decrease in cell contractility is proposed to be critical in 
preventing contraction of the myometrium in pregnant rabbits
59, 60
. Rnd3 is an 
endogenous inhibitor of ROCK1
45
. It binds to ROCK1 to inhibit phosphorylation of 
other ROCK1 downstream targets, such as myosin light chain phosphatase (MYPT1).  In 
cancer, Rnd3 has both pro- and anti- cancer cell migration effects depending on different 
cell types. Rnd3 is down-regulated in aggressive prostate cancers
61
, while it promotes 
melanoma cell invasion, and is highly expressed in colon cancer cells and pancreatic 
tumors
62, 63, 64
.  In the brain, recent studies found that Rnd3 was indispensable in mouse 
neuron development through the Rho kinase-dependent signaling pathway
65, 66, 67
. 
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Genetic deletion of Rnd3 in the mouse was established in our lab. My study suggests that 
loss of Rnd3 results in aqueduct stenosis leading to hydrocephalus through up-regulation 
of Notch signaling
68
.  
 
Study of Rnd3 in Heart 
The biological function of Rnd3 in the heart remains unexplored. One microarray 
screening study showed a significant decrease in the Rnd3 mRNA levels in failing 
human myocardia (Profile GDS651/212724_at/RND3 in NCBI GEO profiles). The 
etiologic meaning of Rnd3 down-regulation in the human failing heart is unknown, 
therefore the investigation of Rnd3 in the heart has clinical significance. In order to 
study the pathological meaning of Rnd3 down-regulation in human heart diseases, our 
lab generated Rnd3 knockout mice, which provided a novel mouse model to address the 
proposed question. 
 
Our lab recently found that the Rnd3-null mice died at the early stage of E11 with heart 
failure and fetal arrhythmias. Ca
2+ 
leakage due to the ryanodine receptor type 2 (RyR2) 
Ca
2+ 
release channels destabilization was detected in embryonic Rnd3
-/- 
cardiomyocytes. 
The Rnd3 deficiency mediated PKA signaling activation was suggested to contribute to 
the impaired Ca
2+ 
homeostasis
69
. Rnd3’s pathological function in the adult heart would 
be our future research emphasis.  
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Cardiac Angiogenesis and Heart Disease 
Angiogenesis and vasculogenesis are two major processes involved in vasculature 
development and pathological remodeling. The former is characterized by vessels 
sprouting from an existing vascular structure, while the latter is the early stage process 
that vessels develop from bone marrow derived endothelial progenitors. Many steps 
have been implicated in angiogenesis: degradation of matrix around endothelium, 
migration and proliferation of endothelial cells, 3-dimentional vessel formation by 
endothelial cells, migration of smooth muscle cells and pericytes to form a mature vessel. 
 
Angiogenesis plays an important role in heart remodeling as an adaptive response to the 
increased demand of oxygen, nutrient and chemokine transportation. In response to 
physiological stimuli, such as the transition from the postnatal to the adult heart, cardiac 
growth occurs predominantly through a hypertrophic process
70
. This postnatal cardiac 
hypertrophy is accompanied by a proportional growth of myocardial vasculature
71
. In 
aerobic exercise, the heart develops physiological hypertrophy along with a 
corresponding growth in coronary microvessels
72, 73
. Besides the physiological stimuli, 
many pathological stimuli such as shear stress, pressure overload, hypoxia and 
inflammation are known to promote cardiac angiogenesis
74, 75
. However, the 
compensatory enhancement of angiogenesis in response to these pathological stimuli 
appears to be insufficient, and this insufficiency is one of the critical factors responsible 
for the transition of the heart from compensated hypertrophy to heart failure
76, 77
. 
Various chemokines and angiogenic growth factors including vascular endothelial 
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growth factor (VEGF)
78, 79
, fibroblast growth factor (FGF)
80
, angiopoietin (Ang)
81
,
endothelin 1 (ET-1)
82, 83, 84
, transforming growth factor-β (TGF-β)85 and NF-κB86 are
considered to be involved in regulating the angiogenesis process. 
Based on the mechanistic study of angiogenesis, the application of pro-angiogenic 
growth factors in heart ischemia rescue and cardiac function improvement has become a 
promising therapeutic strategy. Pro-angiogenic factors such as VEGF and FGF have 
been compensated in myocardial ischemia treatment in many animal studies and clinical 
trials by delivering naked DNA, adenovirus or retrovirus and direct injection of 
recombinant protein. The angiogenic factor administrations have succeeded in animal 
studies
87, 88, 89, 90
, however do not work well in clinical trials. In phase 1 studies, patients
with under-perfused myocardium received a recombinant VEGF (rhVEGF) protein 
intracoronary injection. The clinical results showed that collateral density was increased 
and myocardial perfusion was improved by rhVEGF administration
91, 92
. In the phase II
VIVA (Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis) trial 
178 patients randomly received rhVEGF or a placebo by intracoronary infusion and both 
groups displayed improved exercise tolerance and myocardial perfusion at the endpoint, 
however, without a significant difference
93
. The mechanism underlying the discrepancy
between the preclinical animal studies and practical therapeutic angiogenesis is still not 
known. 
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VEGFs in Angiogenesis Regulation 
VEGF family is one of the predominant pro-angiogenic factors regulating angiogenesis. 
The VEGF family contains 7 members: VEGFA (or VEGF1), VEGFB (or VEGF2), 
VEGFC (or VEGF3), VEGFD, VEGFE, VEGFF and placental growth factor (PlGF). 
Encoded by VEGF gene, different splicing isoforms were found in human: VEGF121, 
VEGF145, VEGF165, VEGF189 and VEGF206. The VEGFs selectively bind to specific 
tyrosine kinase receptors (VEGFR1, VEGFR2 and VEGFR3), which are facilitated by 
co-receptors neuropilin1 and neuropilin2
94
. VEGFR1 (or flt-1) and VEGFR2 (or KDR, 
flk-1) are majorly expressed in endothelium, and can be activated by the binding of 
VEGFA, VEGFB, VEGFC and VEGFD
95, 96
. VEGFR3 (or flt-4) is majorly expressed in 
adult lymphatic endothelium, and functionally restricted to lymphagiogenesis through 
the binding with its ligands VEGFC and VEGFD. 
 
VEGFA is the first discovered VEGF family member, therefore in the earliest study, 
VEGFA was reported as VEGF. The VEGFR2 mediated VEGFA signaling is identified 
as the most important and dominant regulator of angiogenesis and vasculogenesis
97
. 
Deletion of a single VEGFA allele causes embryonic lethality and abnormal vessel 
development
78, 79
. VEGFA has been implicated in promoting endothelial cell survive and 
proliferation, endothelial progenitor cell recruitment, stimulating new vessel formation, 
and in tumor angiogenesis inducing vascular permeability and vasodilation
97, 98, 99, 100
. 
The up-regulation of VEGFA was found in ischemic animal hearts
101, 102, 103
 and acute 
myocardial infarction patients, indicating that VEGFA might be an ischemia induced 
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angiogenic factor. As a major source of VEGFA in the heart, cardiomyocytes secrete 
VEGFA in response to hypoxia and hemodynamic stress. A transcription factor hypoxia-
inducible factor 1 (HIF1α) takes major responsibility for VEGFA expression in the 
hypoxia region
104
. In a recent study, a hypoxia-independent pathway regulating VEGFA
expression by PGC-1α was reported105.
Hypoxia-inducible Factor 1α (HIF1α), a Key Regulator of VEGFA 
Hypoxia-inducible factor (HIF) is a dimer transcription factor composed of α and β 
subunits. The HIFβ subunit is constitutively expressed nuclear protein while the HIFα 
subunit is dynamically regulated and functions in an oxygen-sensitive pattern
104
. The
transcription of HIFα is barely regulated, whereas HIFα can be regulated at the post-
translational level
106. In full oxygenation condition, HIFα is dually regulated through
two different mechanisms. HIF prolyl hydroxylases 1-3 (PHD1-3) make hydroxylation 
modifications on HIFα at the prolyl residues (Pro), resulting in the recruitment of E3 
ubiquitin ligase von Hippel-Lindau (VHL) and undergoing the proteasome 
degradation
107, 108. HIFα also can be hydroxylated at asparaginyl residue (Asn) in the C-
terminal (C-TAD) by HIF asparaginly hydroxylase (FIH). This modification on Asn803 
residue impedes the interaction of HIFα with co-activator p300 in the nucleus resulting 
in repressed transcriptional activity
109
. In hypoxia condition, the activity of PHD and
FIH are repressed consequently stabilizing HIFα protein, suggesting that PHD and FIH 
are cellular oxygen sensors modulating HIFα mediated hypoxia response signaling in an 
oxygen-dependent manner
110
.
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Three isoforms (HIF1α, HIF2α, and HIF3α) are included in the HIFα family. The HIF1α 
and HIF2α share a 48% identity in amino acid sequence and therefore share a similar 
structure and regulation mechanism. To initiate transcriptional activity, both HIF1α and 
HIF2α can translocate from the cytoplasm to the nucleus, forming a heterodimer with 
HIF1β106. The co-activator p300 and CREB binding protein (CBP) facilitate the affinity 
of the HIF heterodimer with the DNA motif hypoxia responsive elements (HREs)
111, 112
.
The downstream target genes are involved in many signaling pathways including 
promoting oxygen delivery (angiogenesis), and inhibiting oxygen consumption 
(glycolysis, lipid metabolism and NO production). VEGFA is one of the most important 
target genes in the regulation of hypoxia induced angiogenesis in cardiac adaptive 
response and tumor growth. Both HIF1α and HIF2α directly regulate VEGFA 
expression in some cell types such as renal carcinoma cells and Hep3B cells. However, 
HIF1α, but not HIF2α, uniquely activates VEGFA expression in mouse embryonic cells, 
indicating that HIF1α is the more potent and dominant regulator of VEGFA113, 114, 115, 116, 
117
. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Source of Human Myocardium 
51 human failing heart samples were obtained from the end-stage heart failure patients at 
the time of transplantation. All heart failure patients have severe impaired cardiac 
function with <20% left ventricular ejection fraction. 12 human normal myocardial 
samples were obtained from the patients died of non-cardiac causes. The Institutional 
Review Board of Methodist Hospital approved all protocols. 
 
Generation of Rnd3 Knockout (KO) and Rnd3/Rock1 Double Knockout (DKO) 
Mouse Lines 
Rnd3 knockout mouse line was derived from a gene trap ES cell line from Texas 
Institute for Genomic Medicine (TIGM). A targeting vector carrying a lacZ expressing 
cassette was inserted into intron 2 of Rnd3 gene. The Rnd3 mutant allele was identified 
by PCR using the primers (5’ to 3’): A148a: TCCATAGAGGGTAAAGCCATCC / 
A148b: AAAGGTACTCCCAGAGAGCTAAGG; 
A148a: TCCATAGAGGGTAAAGCCATCC / A148c: 
ATAAACCCTCTTGCAGTTGCATC. The Rnd3 knockout allele was also confirmed by 
Southern Blotting
69
. The Rnd3-null mice were lethal at E11.5 stage, therefore Rnd3 
haploinsufficient mice were used for mouse line maintenance. 
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The establishment of ROCK1 knockout mouse line was described previously
68
. I 
generated Rnd3
+/-/ROCK1-/-
 mouse line (DKO) by breeding Rnd3
+/- 
with ROCK1
-/- 
mice. 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee of the Texas A&M University Health Science Center. 
 
Mice Work, Fasudil Treatment and Cobalt Chloride (CoCl2) Treatment 
Mice were treated with 1mg/mL Fasudil (LC Laboratories, MA, USA) in drinking water 
for 3 weeks immediately after TAC surgery. Mice were treated with 2mM cobalt 
chloride (Alfa Aesar, 12303, MA, USA) in drinking water for 3 weeks immediately after 
TAC surgery. All animal experiments were approved by the Institutional Animal Care 
and Use Committee of the Texas A&M University Health Science Center. 
 
Cardiac Function Assessment by Echocardiography 
Cardiac functions were measured using a Vevo770 High-Resolution In Vivo Micro-
Imaging System (VisualSonics, Toronto, ON, Canada) with a RMV-707B probe. 10-15 
weeks old male mice were anesthetized with 3% isoflurane mixed with 100% oxygen, 
then followed by the anesthetization with 1-1.5% isoflurane. After the mice heart rate 
decreased to 380-420 beats per min, the 2-D echocardiography of anterior (+septum) and 
posterior walls were recorded at the papillary muscles level. 
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Transverse Aortic Constriction (TAC) 
10-15 weeks old adult male mice were anesthetized with 3% isoflurane mixed with 100% 
oxygen. After the thymus was retracted and the transverse aorta was exposed, a 3mm 
length of 27 gauge needle was put besides the aorta between the right innominate and 
left carotid artery. The aortic constriction was performed by tying a 6-0 suture against 
the needle. By removing the needle after two knots the constriction was achieved. The 
procedure yielded a 60%-80% constriction on transverse aorta diameter. After the 
surgery, the artery flow velocity was measured by Doppler (Indus Instruments, Houston, 
USA), and the ratio of right-to-left carotid artery flow velocity was calculated. To 
minimize surgery variation, the mice with the ratio between 5 and 10 were used for 
further experiments. Sham group without occlusion served as a control. All TAC surgery 
induced pressure overload lasted for 3 weeks. 
 
Blood Pressure Assessment 
Mouse was trained for 3 days until it stayed quiet in the animal holder of Mouse Blood 
Pressure System (MRBP-MMC, IITC Life Science Inc, CA, USA). Systolic blood 
pressure was assessed through tail cuff method, and diastolic blood pressure was 
calculated by software MRBP Monitor Version 1.59. 
 
Coronary Flow Reserve Assessment by Doppler 
Mouse coronary flow reserve was measured using MM3 system (World Precision 
Instruments, FL, USA) with a Pulsed Doppler probe (Indus Instruments, TX, USA). The 
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method was modified from George E. Taffet’s lab118. 10-15 weeks old male mice were 
anesthetized with 2% isoflurane mixed with 100% oxygen, then followed by the 
anesthetization with 2.5% isoflurane (hyperemic condition) and 1% isoflurane (basal 
condition), respectively. The peak flow velocities in left main coronary were recorded 
under the hyperemic condition and the basal condition, respectively. The ratio of 
hyperemic over basal coronary velocity was considered as the index of coronary flow 
reserve. 
 
Hematoxylin and Eosin Staining, Immunostaining and Immunoblotting  
Mice hearts were perfused and fixed by Langendorff Perfusion System (Radnoti, 
120108). The whole heart paraffin sections were applied to Hematoxylin and Eosin 
Staining (51275, Fluka; HT110132-1L, Sigma-Aldrich) and terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining (In situ cell death detection kit, 
11684795910, Roche, USA). Phalloidin staining (A12381, Invitrogen, USA) and DAPI 
staining were used to label F-actin and nuclei, respectively. Isolectin GS-IB4 staining 
(I21411, Invitrogen, NY, USA) was used to visualize capillaries. For each heart sample, 
images from 5 fields were acquired by Leica DM2000 fluorescence microscopy (Leica 
Microsystems Inc., IL, USA). One image was from the top of interventricular septum 
and four images were from the left ventricle wall. The images for TUNEL staining 
results were quantified by Leica Application Suite Imaging Software (Version 4.0, 
Germany). 
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Protein samples for immunoblotting were extracted and separated from mice hearts as 
described previously
119
. Antibodies from the following sources: Caspase-3 (sc-7148)
from Santa Cruz Biotechnology (CA, USA); MLC2 (PA5-17624), Phospho-Thr18/Ser19 
MLC (PA5-17727) from Thermo Scientific Pierce (IL, USA); MYPT1 (2634S), 
Phospho-T853 MYPT1 (4563S) from Cell Signaling Technology (MA, USA); c-Myc 
(sc-40) and HA (sc-805) from Santa Cruz Biotechnology (CA, USA); VEGF (ab1316) 
from abcam (MA, USA); HIF-1 alpha (H1alpha67) from Novus Biologicals (CO, USA) 
are commercially available. Rnd3 antibody was made from Cocalico Biologicals (PA, 
USA). Protein loading was normalized by the GAPDH (Santa Cruz, sc-20357) blotting 
intensity. 
Hypoxyprobe-1 Staining 
For in vivo hypoxia region detection, HP1-100Kit was used (Hypoxyprobe Inc, MA, 
USA). Mice were intraperitoneal injected 80mg/kg Hypoxyprobe
TM
-1, and sacrificed 60
min later. The Hypoxyprobe
TM
-1 deposited at hypoxia region. Hearts were harvested and
processed for paraffin embedding. Anti-mouse IgG (MAb1, Hypoxyprobe Inc, MA, 
USA) immunostaining was performed to detect the Hypoxyprobe
TM
-1 in cardiac sections.
Cardiomycyte Isolation 
10-15 week-old adult male mouse was sacrificed, and the heart was harvested and 
transferred to perfusion buffer immediately. Transverse aorta was cannulated by a 22 G 
cannula, and was tied to the cannula before the cannula tip reached aortic valve. Then 
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the heart was uploaded to Langendorff Perfusion System (120108, Radnoti, CA, USA) 
for the following enzyme digestion. Briefly, the heart was continually perfused at 37°C 
by the digestion buffer containing 0.15 mg/mL Liberase TM (05401127001, Roche, IN, 
USA). The digestion process lasted 8-10 min. After digestion, the heart became swelled 
and soft. The digestion was terminated by 5% fetal bovine serum (FBS) and 
cardiomyocytes were carefully dissociated. After calcium reintroduction, the 
cardiomyocytes were seeded onto laminin-coated dishes. MEM medium containing 5% 
FBS was used for the cardiomyocyte culture. After the cells were cultured for 16 hours, 
the conditional medium was collected for the following HUVECs tube formation assay 
and ELISA assay. 
 
Tube Formation Assay, Cell Culture, Hypoxia Treatment and Gene Transient 
Transfection 
Human umbilical vein endothelial cells (HUVECs) were cultured in EGM medium (CC-
3162, Lonza, NJ, USA) for 24 hours in advance to the tube formation assay. Then the 
HUVECs were trypsinized and seeded onto BME gel (3433-005-01, Trevigen, MD, 
USA) coated dishes with non-growth factor EBM medium (CC-3156, Lonza, NJ, USA). 
After the cell attachment, the EBM medium was replaced by the cardiomyocyte 
conditional medium for the following HUVECs tube formation process. The tube 
structures were matured after 6 hours. Images were acquired under 5 x magnifications, 
and analyzed by WimTube Image Analysis software (ibidi GmbH, Germany). 
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Hela cell line was cultured in DMEM medium containing 10% FBS for in vitro 
experiments, including luciferases assay and immunoprecipitation. 
 
For hypoxia treatment, cell culture dishes were put into hypoxic condition chamber 
(MIC-101, Billups-Rothenberg Inc, CA, USA). The cells were cultured in 1% O2 for 16 
hours. 
 
siRNA specific for human RND3 knockdown was purchased from Thermo Scientific (L-
007794-00-0050). Expression construct human HA-HIF1alpha-pcDNA3 
(plasmid#18949) was purchased from Addgene; construct GST-Rnd3 was generated 
with pGEX-6P-1 backbone (GE Healthcare); construct myc-Rnd3 was generated as 
described previously
68
. 
 
VEGFA Measurement 
VEGFA protein level in cardiomyocyte conditional medium was assessed by the 
commercially available VEGF Mouse ELISA Kit (ab100751, abcam, MA, USA). The 
whole process included the following multiple steps. 1. Sample preparation: WT and 
Rnd3
+/-
 cardiomyocyte conditional medium were harvested after 16h-cell culture, and 
the supernatant was collected after centrifuge. The supernatant was ready for VEGFA 
measurement. 2. Sample loading: VEGFA standards were prepared as the manufacture 
described. The supernatant from the medium was diluted by 4 folds. The standards and 
the samples were loaded to the 96-well plate which had been coated with VEGFA 
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primary antibody. Duplicate loadings were applied to minimize variance. 3. 
Measurement: The samples were incubated with the primary antibodies at 4°C for 
overnight, followed by wash processes. The biotinylated second antibody was incubated 
with the sample-primary antibody complex in the plate for 1 hour at room temperature. 
After the immune binding process, the substrate of biotin was added to each well, and 
the reactions were terminated after 45 min. The optical density was measured by a 
microplate reader at 450 nm immediately. 
QPCR (quantitative polymerase chain reaction) Analysis 
Transcripts were quantified by StepOnePlus
TM 
Real-Time PCR Systems (Applied
Biosystems, CA, USA) with SYBR Green master mixes buffer system (4367659, life 
technologies, NY, USA). Total RNAs was extracted by TRIzol (15596-026, life 
technologies, NY, USA). The forward / reverse QPCR primers (5′ to 3′) were as follows: 
VEGFA (mouse): CTGTGCAGGCTGCTGTAACG/GTTCCCGAAACCCTGAGGAG; 
GAPDH (mouse): GAGTCAACGGATTTGGTCGT/TTGATTTTGGAGGGATCTCG. 
Luciferase Assay 
Luciferase report vector with a VEGFA promoter composed by three HIF1 response 
elements is commercially available (HRE-luciferase, plasmid #26731, Addgene). Renilla 
luciferase vector (E1960, Promega) served as a control. Transient transfection of vectors 
into Hela cell line was described previously
120
. The luciferase assay was performed 36
hours after post-transfection. Cells were lysed by the buffer from Promega (E3971), and 
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20 of 150 µl lysis supernatant were used for assay. A lumat3 LB9508 luminometer 
(Berthold) was used to read out optical density. Each sample measurement was 
triplicated to minimize variance. 
Statistical Analysis 
Data are presented as means ± s.d. Unpaired, two-tailed student’s t test was used for two 
group comparisons. One-way ANOVA followed by Student-Newman-Keuls test was 
used for multiple group comparisons. Chi-square Fisher’s test was used for survival rate 
statistical analysis. All statistical analyses were performed in software SigmaPlot 11.0 
(Systat, San Jose, CA, USA). The P value < 0.05 was considered as significant 
difference. 
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CHAPTER III 
RESULTS 
RND3 is Down-regulated in End-point Stage Human Failing Hearts 
The clinical pathological significance of Rnd3 in heart is barely reported. 
A RNA microarray study from NCBI database has probed the mRNA levels of Rnd3 
from normal human hearts, idiopathic dilated failing human hearts and ischemic failing 
human hearts. Significantly reduced Rnd3 mRNA levels were found in those heart 
failure patients (Profile GDS651/212724_at/RND3 in NCBI GEO profiles). To explore 
the RND3 protein expression profile in human pathological hearts, 51 human failing 
heart samples and 12 normal heart samples were analyzed by RND3 immunoblotting. 
In the heart samples from the end-point stage heart failure patients, RND3 protein levels 
significantly decreased compared with the human normal hearts (Figure 1a). The 
densitometry of RND3 protein levels were normalized by GAPDH, and the average 
RND3 level in the failing hearts was down-regulated by 57.9% compared with the 
normal hearts (Figure 1b). 
The down-regulation of RND3 expression in human failing hearts suggested an 
important modulatory role of RND3 in the etiology of the transition of the heart to 
failure. To investigate the pathological significance of RND3 down-regulation in human 
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hearts, Rnd3 knockout mouse line was generated to recapitulate the situation observed in 
heart failure patients. 
Figure 1. RND3 Protein Levels were Down-Regulated in Failing Human Hearts. (a) 
Representative image for immunoblotting of RND3 and GAPDH in human normal 
hearts and human failing hearts. (b) Densitometry quantification of RND3 protein levels 
from 12 human normal hearts and 51 human failing hearts normalized by GAPDH. 
Unpaired, two-tailed student’s t test was used for two group comparisons. The P value < 
0.05 was considered as significant difference. Data are presented as means ± s.d.  
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Rnd3
+/-
 Haploinsufficient Mice Displayed Normal Heart Morphology and Cardiac 
Function 
To investigate the Rnd3's function in mouse heart, Rnd3 gene trap knockout mouse line 
was generated. Rnd3
-/- 
mice were lethal at embryo E11.0 stage associated with heart 
failure and arrhythmia, however, Rnd3
+/- 
haploinsufficient mice were viable and 
displayed no abnormal phenotype under physiological condition.  
 
The heart morphology and cardiac function were detected in Rnd3
+/- 
10-12 weeks old 
male mice by echocardiography. Based on the doppler signals of live hearts, in Rnd3
+/- 
adult hearts, interventricular septum thickness (IVS), left ventricle inner dimension 
(LVID) and left ventricle posterior wall thickness (LVPW) showed no difference 
compared with wild type (WT) hearts (Table 1). The cardiac capability of pumping 
blood out from ventricle was described by stroke volume, ejection fraction, fractional 
shortening and cardiac output. The mutant hearts also displayed normal cardiac function 
compared with the WT hearts (Table 1). 
 
The impaired cardiac function in Rnd3
-/- 
homozygous mouse embryos suggests Rnd3's 
essential role in the embryonic heart development. However the Rnd3's function in adult 
heart remodeling was unexplored. Under physiological condition the Rnd3
+/- 
mice 
exhibited the normal heart phenotype. To investigate the response under pathological 
condition, a challenge would be performed on these mice. 
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Table 1. Rnd3
+/-
 Mice Displayed No Abnormality in Heart Morphology and Cardiac 
Function Compared to Wild-Type (WT) Mice. Echocardiography assessments of heart 
morphology and cardiac function were performed in 7 pairs of 10-15 weeks-old WT and 
Rnd3
+/-
 male mice. No significant difference was detected. IVS: interventricular septum 
thickness; LVID: left ventricle inner dimension; LVPW: left ventricle posterior wall 
thickness; d: diastolic; s: systolic. Statistical significance was determined by unpaired, 
two-tailed student’s t test. Data are means ± s.d.  
 
 
 
 
 
Rnd3
+/-
 Mice were Predisposed to Transverse Aortic Constriction (TAC) Induced 
Hemodynamic Stress and Developed Heart Failure Associated with Dilated 
Cardiomyopathy Phenotype 
The hemodynamic stress induced by transverse aortic constriction (TAC) surgery was 
broadly used on rodents to generate pressure overload and induce heart remodeling. The 
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TAC surgery could induce multiple heart diseases including cardiac fibrosis, apoptosis 
and hypertrophy. These animal models greatly facilitate the research study in cardiology 
field. According to the echocardiography analysis results, Rnd3
+/- 
mice were viable and 
exhibited normal cardiac function and morphology at basal condition. To investigate 
Rnd3’s role in pathological heart, the Rnd3+/- mice and WT mice were exposed to TAC 
stress for 3 weeks.  
 
The whole animal hearts were harvested and morphology changes were observed after 
TAC surgery. Thick left ventricular posterior wall and enlarged chamber were observed 
in the WT heart after TAC challenge, indicative of compensatory hypertrophy in 
response to stress (Figure 2a, WT TAC); however, the Rnd3
+/- 
heart displayed much 
larger left ventricular chamber and even thinner ventricular wall after TAC, indicative of 
a dilated cardiomyopathy phenotype (Figure 2a, Rnd3
+/- 
TAC). This typical dilated 
cardiomyopathy phenotype in the mutant heart after TAC suggested damaged cardiac 
function. Detected by echocardiography, ejection fraction (EF) and fractional shortening 
(FS) of the Rnd3
+/- 
mice heart decreased dramatically from 66.7% and 36.8% to 15.1% 
and 6.7%, respectively, indicating that heart failure happened in the Rnd3
+/- 
mice heart 
under hemodynamic stress (Figure 2b). Consistent with the echocardiographic results, 
lung edema was observed (data not shown) and significant increase in lung weight (LW) 
was detected in the Rnd3
+/- 
mice, which confirmed the heart failure development (Figure 
2c). 
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Figure 2. Rnd3
+/-
 Mice Developed Heart Failure 3 Weeks after Transverse Aortic
Constriction (TAC) Surgery. (a) Representative images for whole hearts and 
Hematoxylin and Eosin stained cardiac sections for wild type (WT) and Rnd3
+/- 
mice
before and after TAC surgery. The mutant hearts were enlarged in response to TAC 
stress. (b) Significant decrease in cardiac function determined by ejection fraction (EF) 
and fractional shortening (FS) was detected in Rnd3
+/- 
mice comparing with WT mice
after TAC. (c) Significant increases in the ratio of lung weight (LW) over body weight 
(BW) and the ratio of LW over tibia length (TL) were observed in Rnd3
+/- 
mice
comparing with WT mice after TAC, indicating heart failure development. The number 
in each column represents animal numbers in each group. One-way ANOVA followed 
by Student-Newman-Keuls test was used for multiple group comparisons. The P value < 
0.05 was considered as significant difference. Data are presented as means ± s.d.  Scale 
bar represents 1mm. 
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To confirm the cardiac phenotype, left ventricular internal dimension at systole (LVIDs) 
and left ventricular posterior wall thickness at systole (LVPWs) were assessed via 
echocardiography (Figure 3a, b). The sham group WT and Rnd3
+/- 
hearts exhibited no 
significant difference, while after TAC the LVIDs of the Rnd3
+/- 
heart dramatically 
increased from 2.47 mm to 4.05 mm and the LVPWs declined from 1.09 mm to 0.68 
mm (Figure 3b). In line with the cardiac dysfunction, the Rnd3
+/- 
mice displayed higher 
mortality during the 3 weeks after TAC surgery compared with the WT control. The 
survival rates of these two genotype mice lines started to exhibit significant difference at 
the 7
th
 day post-TAC. And at the end-time point (21
th
 day), the survival rate of the 
mutant mice decreased to 75%, while the WT mice displayed a 93% survival rate 
(Figure 3c). 
 
The Rnd3 deficient mice are predisposed to TAC induced hemodynamic stress, and 
developed heart failure with dilated cardiomyopathy phenotype, which suggests that 
Rnd3 plays an essential role in the transition of chronic heart failure.  
 
Severe Cardiac Apoptosis was Detected in the Rnd3
+/- 
Heart
 
after TAC 
It's well known that loss of cardiomyocytes results in heart dysfunction and dilated 
cardiomyopathy. To investigate the underlying mechanism of the Rnd3
+/- 
heart failure 
development induced by TAC, I examined the hearts using histological and molecular 
analyses. 
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Figure 3. Rnd3
+/-
 Mice Developed Dilated Cardiomyopathy Phenotype Induced by 
Pressure Overload. (a) Representative images from echocardiography indicate the 
enlarged left ventricle and thin left ventricular posterior wall in post-TAC Rnd3
+/- 
mice. 
(b) Quantification of parameters LVIDs and LVPWs determined by echocardiography 
confirmed the dilated cardiomyopathy phenotype in Rnd3
+/- 
heart induced by TAC. (c) 
Rnd3
+/- 
mice exhibited a lower survival rate compared to the WT mice in 3 weeks after 
TAC. The number in each column represents animal numbers in each group. One-way 
ANOVA followed by Student-Newman-Keuls test was used for multiple group 
comparisons. The P value < 0.05 was considered as significant difference. Data are 
presented as means ± s.d.  Scale bar represents 1mm. SP: septum; LVIDs: left 
ventricular internal dimension at systole; LVPWs: left ventricular posterior wall 
thickness at systole. 
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I harvested the hearts from the WT and Rnd3
+/- 
mice before and after TAC, and analyzed
the heart sections by terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL), which is an immunochemical method to identify apoptotic cells. 
Cardiomyocytes were identified by F-actin immunochemical staining. Significant 
amount of apoptotic cardiomyocytes were observed in the mutant hearts compared with 
the WT hearts after TAC surgery (Figure 4a, b). Along with the histological analysis, the 
immunoblottings of caspase 3 were probed by antibody to detect the activation of 
caspase 3 in animal hearts. Increased active caspase 3 level was detected in the Rnd3
+/- 
hearts after TAC, indicating the cardiac apoptosis development (Figure 4c, d). 
Under hemodynamic stress the Rnd3
+/-
 mice developed severe cardiac apoptosis, which
suggested a potential mechanism in the Rnd3 deficiency mediated cardiomyopathy. 
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Figure 4. Rnd3
+/-
 Mice Developed Cardiac Apoptosis in Response to TAC. (a) 
Representative images showed green fluoresce of terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) stained sections from WT and Rnd3
+/-
 hearts after 
TAC. The images were overlapped with blue fluoresce of nuclei counter-staining. 
Cardiomyocytes were visualized by red fluoresce of F-actin Phalloidin staining. Arrows 
point at TUNEL positive cardiomyocytes. (b) Significant increases in TUNEL positive 
cardiomyocytes number were observed in Rnd3
+/- 
hearts after TAC. Cell numbers were 
quantified by LAS V4.0 software. (c) Higher active caspase 3 levels were detected in 
Rnd3
+/-
 hearts compared with WT control after TAC. (d) Densitometry quantification of 
active caspase 3 levels normalized by GAPDH. Casp3: Caspase 3; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase. The number in each column represents 
animal numbers in each group. One-way ANOVA followed by Student-Newman-Keuls 
test was used for multiple group comparisons. Unpaired, two-tailed student’s t test was 
used for two group comparisons. The P value < 0.05 was considered as significant 
difference. Data are presented as means ± s.d.  Scale bar represents 10µm.  
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Complete Deletion of Rnd3 Gene Spontaneously Resulted in Cardiac Apoptosis  
The Rnd3-null mice were lethal appropriately at E11.0 stage with the heart failure 
developed at E10.5 stage. To investigate if loss of Rnd3 gene would spontaneously result 
in cardiac apoptosis in physiological condition, the Rnd3-null embryonic hearts at E10.5 
stage were adopted for histological analysis. 
 
I collected Rnd3
-/- 
hearts at E10.5 embryo stage and conducted TUNEL staining on the 
embryonic heart sections. Consistent with the apoptosis phenotype in the TAC stress 
remodeled adult Rnd3
+/-
 heart, significant amount of apoptotic cardiomyocytes were also 
observed in the Rnd3
-/- 
embryonic hearts under basal condition (Figure 5a, b). 40 pairs of 
WT and mutant embryonic hearts were collected for further immunoblotting analysis. 
The dramatically increased activity of apoptosis marker caspase 3 further confirmed the 
apoptosis phenotype in the Rnd3-null embryonic hearts (Figure 5c).  
 
Along with the high lethality at embryo E11.0 stage, Rnd3
-/- 
mice spontaneously 
developed heart failure and cardiac apoptosis at E10.5 stage. This result is consistent 
with the phenomenon in the post-TAC Rnd3
+/- 
mice. Rnd3 deficiency is closely 
associated with the cardiac apoptosis, which is a novel discovery and probably can 
explain the meaning of Rnd3's down-regulation in the human failing hearts. 
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Figure 5. Severe Cardiac Apoptosis was Observed in the Rnd3
-/- 
Embryonic Hearts at the
E10.5 Stage. (a) Representative images showed green fluoresce of TUNEL stained WT 
and Rnd3
-/- 
E10.5 embryonic cardiac sections. Cardiomyocytes were visualized by red
fluoresce of F-actin Phalloidin staining. Arrows point at TUNEL positive 
cardiomyocytes. Scale bars represent 50µm and 20 µm, respectively. (b) Significant 
amounts of TUNEL positive cardiomyoctes were detected in Rnd3
-/- 
embryonic hearts
compared with WT controls. (c) Significant increased caspase 3 activities were detected 
in 40 Rnd3
-/- 
embryonic hearts compared with 40 WT controls. Immunoblotting results
were quantified by densitometry analysis. Casp3: Caspase 3; GAPDH: glyceraldehyde 3-
phosphate dehydrogenase. The number in each column represents animal numbers in 
each group. Unpaired, two-tailed student’s t test was used for two group comparisons. 
The P value < 0.05 was considered as significant difference. Data are presented as means 
± s.d. 
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Rnd3 Deficiency Resulted in Cardiac Responsive Angiogenesis Defect 
Responsive angiogenesis plays a vital role in cardiac repair after the exposure to 
ischemic stress. The heart needs microvessels to transport nutrients and oxygen. In 
chronic heart remodeling, both responsive angiogenesis and vasculogenesis are 
stimulated. This process is modulated by the co-work of chemokines, cytokines and 
growth factors. Compensatory angiogenesis disorder results in cardiac dysfunction, even 
heart failure. I analyzed microvasculature generation in the WT and the Rnd3
+/-
 hearts
and observed a second phenotype that Rnd3 deficiency resulted in cardiac responsive 
angiogenesis defect. 
By labeling the endothelial cells with Isolectin-B4, the capillaries in cardiac tissue were 
visualized. The images were analyzed by LAS image analysis system, and the 
angiogenesis status was quantified based on the capillary areas and numbers. The WT 
and the Rnd3
+/- 
hearts in sham group exhibited similar capillary number and area (Figure
6a, b, Sham). As I expected, the hemodynamic stress stimulated the angiogenesis 
compensation in the WT heart; however, in the mutant
 
heart the responsive angiogenesis 
was failed. Smaller capillary areas and fewer capillary numbers were detected in the 
post-TAC Rnd3
+/- 
heart compared to the WT control (Figure 6a, b, TAC).
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Figure 6. Rnd3
+/-
 Heart Developed Responsive Angiogenesis Defect under
Hemodynamic Stress. (a) Isolectin-B4 stained cardiac capillaries (green) from WT and 
Rnd3
+/- 
heart tissue sections before and after TAC. Nucleuses were visualized by blue
DAPI staining. (b) Capillary area and number were quantified by LAS V4.0 software. 
Significant decreases in Rnd3
+/- 
hearts were detected. The number in each column
represents animal numbers in each group. One-way ANOVA followed by Student-
Newman-Keuls test was used for multiple group comparisons. The p value < 0.05 was 
considered as significant difference. Data are presented as means ± s.d.  Scale bar 
represents 25µm. 
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Coronary flow reserve (CFR) is a velocity index for blood flow through the capillaries 
derived from coronary artery. To estimate coronary capillary circulation, the CFR was 
assessed before and after TAC. The Rnd3
+/- 
heart displayed similar microvessel function
compared with the WT heart prior to TAC stress (Figure 7a, Sham). In response to stress, 
a 20.8% reduction of CFR was detected in the Rnd3
+/- 
mice compared with the WT
control, indicating the defective microvessel function in the Rnd3 mutant heart (Figure 
7a, TAC). 
The angiogenesis defect and ischemia induced hypoxia always serves as an indicator for 
testing angiogenesis deficiency in vivo. A chemical reagent, hypoxyprobe-1, can deposit 
to hypoxia region in live animal and can be visualized by immunohistochemical staining. 
Using this method, I observed a 5.9-fold increase in hypoxic area in the Rnd3
+/- 
hearts
compared with the WT control after TAC (Figure 7b, c). 
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Figure 7. Rnd3
+/-
 Heart Developed Impaired Coronary Perfusion under Hemodynamic 
Stress. (a) Rnd3
+/- 
mice displayed a reduction of coronary flow reserve after stress. (b) 
Hypoxic regions were labeled by Hypoxyprobe-1 staining (brown). Rnd3
+/- 
cardiac 
tissue showed extensive hypoxia response compared with WT control after TAC. (c) 
Quantification of hypoxic area in WT and Rnd3
+/- 
cardiac sections. A 5.9-fold increase 
was detected in Rnd3
+/- 
hearts. The number in each column represents animal numbers in 
each group. One-way ANOVA followed by Student-Newman-Keuls test was used for 
multiple group comparisons. The p value < 0.05 was considered as significant difference. 
Data are presented as means ± s.d.  Scale bar represents 25µm. 
 
 
 
 
 
Evidenced by capillary histological analysis, circulation function assessment and 
hypoxic area measurement, the Rnd3
+/- 
mice developed responsive angiogenesis disorder 
in heart under stress. Rnd3 deficiency mediated heart failure and dilated cardiomyopathy 
probably not only due to the increased cardiac apoptosis, but also due to the 
compromised compensatory ability to generate the functional new microvessels. 
Because of these two phenotypes, I will illustrate two different mechanisms to explain 
how Rnd3 takes part in the heart failure development. 
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Rho Kinase 1 Signaling Pathway was Activated by Rnd3 Gene Deletion 
Our lab's previous work has reported that Rho kinase 1 (ROCK1) is activated in human 
end-point failing hearts. And the activation has been implicated in cardiac apoptosis 
through manipulating the PTEN/Akt pathway mediated activation of caspase 3
42
. 
Therefore it's a logical thinking that Rnd3, the endogenous inhibitor of ROCK1, 
probably also plays a regulatory role in apoptosis, contributing to the dilated 
cardiomyopathy in vivo. 
 
The activity of ROCK1 in the mouse hearts was detected by immunoblotting. Myosin 
phosphatase target subunit 1 (MYPT1) and myosin light chain 2 (MLC2) served as the 
substrates of ROCK1. The phosphorylation status of these substrates indicated the 
activity of ROCK1. Hyper-phosphorylated MYPT1 was observed in the Rnd3
+/-
 hearts 
after TAC, indicative of the elevated ROCK1 activity (Figure 8a, b). Meanwhile, I also 
detected ROCK1 pathway in Rnd3
-/- 
hearts at embryo E10.5 stage. Again, the ROCK1 
pathway was significantly activated by complete deletion of Rnd3, determined by the 
hyper-phosphorylated MYPT1 and MLC2 (Figure 8c, d).  
 
Associated with the heart failure and apoptotic phenotype, the elevation of ROCK1 
signaling pathway was detected in the Rnd3
-/- 
embryo hearts under physiological 
condition and in the Rnd3
+/-
 hearts under pathological condition. These data suggested 
that the Rnd3 deficiency mediated cardiac apoptosis probably due to the activation of 
ROCK1. 
 
44 
Figure 8. Activation of ROCK1 Signaling Pathway was Observed in the Rnd3
+/-
 Heart
Post-TAC as Well as in the Rnd3
-/-
 Embryonic Heart. (a) Elevated ROCK1 activities
were observed in Rnd3
+/-
 hearts compared with WT hearts after TAC, determined by the
increased ROCK1 substrate MYPT1 phosphorylation level. (b) Densitometry 
quantification of p-MYPT1 levels normalized by total MYPT1. (c) Increased 
phosphorylation levels of ROCK1 substrate MYPT1 and MLC2 demonstrated elevated 
ROCK1 activities in Rnd3-null hearts. (d) Densitometry quantifications of p-MYPT1 
levels normalized by total MYPT1, and p-MLC2 levels normalized by total MLC2. 
ROCK1: Rho kinase 1; MYPT1: myosin phosphatase target subunit 1; MLC2: myosin 
light chain 2. The number in each column represents animal numbers in each group. 
Unpaired, two-tailed student’s t test was used for two group comparisons. The P value < 
0.05 was considered as significant difference. Data are presented as means ± s.d.  
Rho Kinase Inhibitor, Fasudil Partially Rescued Heart Failure and Cardiac 
Apoptosis in the Rnd3
+/- 
Heart after TAC
The Rnd3
+/- 
mice were predisposed to hemodynamic stress and developed cardiac
apoptosis, which is consistent with the phenotype in Rnd3 null mice at embryonic stage. 
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More evidences showed that the activated ROCK1 pathway was closely associated with 
the apoptosis in Rnd3 deficient hearts. Since Rnd3 can physically bind to and suppress 
ROCK1 activity, I hypothesized that Rnd3 deficiency mediated cardiac apoptosis 
probably through the ROCK1 activation. To verify this hypothesis, I conducted a rescue 
experiment by the application of Fasudil, a clinical used ROCK1 inhibitor.   
 
Mice were exposed to the hemodynamic stress and the Fasudil was administrated 
immediately after TAC surgery. Treatment and TAC stress were lasted for three weeks. 
Echocardiographs were recorded for the assessments of cardiac function and 
morphological remodeling. Cardiac functions in the post-TAC Rnd3
+/- 
mice were 
significantly improved by Fasudil compared with the non-treated mice. The increases in 
ejection fraction (EF) and fractional shortening (FS) were observed from 19.1% and 8.6% 
to 40.3% and 19.5%, respectively (Figure 9a). However, these improvements did not 
make the heart function been fully rescued. The pressure overloading stimulated 
myocardium apoptosis in the Rnd3
+/- 
heart was attenuated by the Fasudil treatment 
(Figure 9b). The apoptotic cardiomyocyte number was reduced by 63.5% after the 
treatment (Figure 9c). Along with the decrease in apoptotic cell number, the up-
regulation of active caspase 3 protein level in the post-TAC Rnd3
+/- 
heart was 
significantly eased by Fasudil (Figure 9d, e). Western blotting of the phosphorylated 
ROCK1 substrate, MYPT1, demonstrated that ROCK1 signaling was repressed by the 
Fasudil (Figure 9f, g).  
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Figure 9. Rnd3 Deficiency Mediated Apoptotic Cardiomyopathy and Heart Failure were 
Partially Rescued by ROCK1 Inhibitor Fasudil. (a) Cardiac functions for sham, TAC and 
TAC plus Fasudil groups measured by echocardiography. (b) Representative images 
showed green fluoresce of TUNEL stained Rnd3
+/-
cardiac sections from sham, TAC and 
TAC plus Fasudil groups. The images were overlapped with blue fluoresce of nuclei 
counter-staining. Cardiomyocytes were visualized by red fluoresce of F-actin Phalloidin 
staining. Arrows point at TUNEL positive cardiomyocytes. (c) Less TUNEL positive 
cardiomyocytes were observed in Fasudil treated Rnd3
+/- 
mice heart after TAC. (d) 
Immunoblotting of apoptosis marker full-length Casp3 and active Casp3 in Rnd3
+/- 
mice 
heart before and after TAC, with and without Fasudil treatment. (e) Densitometry 
analysis for active Casp3 level normalized by GAPDH. (f) Immunoblotting of ROCK1 
substrate p-T853 MYPT1 and total MYPT1 in Rnd3
+/- 
mice heart before and after TAC, 
with and without Fasudil treatment. (g) Densitometry analysis for p-MYPT1 level 
normalized by total MYPT1. The number in each column represents animal numbers in 
each group. One-way ANOVA followed by Student-Newman-Keuls test was used for 
multiple group comparisons. The P value < 0.05 was considered as significant difference. 
Data are presented as means ± s.d. Scale bar represents 10µm. 
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Figure 9. Continued. 
 
 
 
 
Given that ROCK1 modulates smooth muscle contractility through regulating actin 
assembly, ROCK1 plays a critical role in control of vessel tone and blood pressure. 
Fasudil is a selective Rho kinases inhibitor and vasodilator. To delineate whether the 
improved cardiac phenotype was not due to Fasudil mediated vasodilation, I assessed 
both systolic blood pressure and diastolic blood pressure for the WT mice and Rnd3
+/- 
mice before and after TAC, with or without Fasudil treatment. The Rnd3
+/- 
mice 
exhibited no significant blood pressure changes among these multiple groups compared 
with the WT mice (Figure 10).  
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In this rescue experiment, blockage of ROCK1 pathway significantly ameliorated heart 
failure and apoptosis in Rnd3 mutant heart after surgery. Therefore, the Rnd3 deficiency 
mediated apoptotic cardiomyopathy is partially regulated by the ROCK1 signaling 
pathway activation. 
Figure 10. Blood Pressures of the WT and the Rnd3+/- Mice were Not Changed after 
Fasudil Treatment. (a) Systolic blood pressure was assessed in the WT and the Rnd3
+/- 
mice among multiple groups. (b) Diastolic blood pressure was calculated based on the 
systolic blood pressure. The number in each column represents animal numbers in each 
group. Kruskal-Wallis One Way ANOVA on Ranks followed by Dunn’s method was 
used for multiple group comparisons. The P value < 0.05 was considered as significant 
difference. Data are presented as means ± s.d. 
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Genetic Deletion of ROCK1 Attenuated Rnd3 Deficiency Mediated Apoptotic 
Cardiomyopathy 
The Fasudil in vivo rescue experiment indicated that cardiac apoptosis in Rnd3 knockout 
mice may partially due to the activation of ROCK1 signaling. However, the potential 
side-effect and non-specificity of the Fasudil weakened the conclusion. To further 
demonstrate that the ROCK1 activation mechanism was responsible for the Rnd3 
deficiency-mediated cardiomyopathy, a second animal rescue experiment was performed. 
Genetic deletion of ROCK1 was the other strategy to verify the ROCK1 pathway in 
Rnd3 defective mice. 
 
I generated a double-knockout (DKO) mouse line with the genotype of Rnd3
+/-/ROCK1-/-
 
(Figure 11a). The DKO mice exhibited normal cardiac function under physiological 
condition (Figure 11b, Sham). Then, both of the Rnd3
+/- 
mice and Rnd3
+/-/ROCK1-/-
 mice 
were exposed to the TAC surgery induced cardiac pressure overload. Echocardiography 
was recorded 3 weeks post the surgery. Consistent with the previous studies, the Rnd3
+/- 
mice developed heart failure. However, the post-TAC cardiac function in Rnd3
+/-/ROCK1-/-
 
mice (EF 52.9% and FS 26.5%) was much better than Rnd3
+/- 
mice (EF 19.9% and FS 
8.9%) (Figure 11b, TAC). Cardiac apoptosis was compared in both two mouse lines. 
Less TUNEL positive cardiomycytes numbers as well as lower active casepase 3 level 
were observed in the DKO mice compared with the Rnd3
+/- 
mice (Figure 11c to f).  
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Figure 11. Genetic Deletion of ROCK1 Partially Improved Cardiac Function and 
Attenuated Apoptosis in the Post-TAC Rnd3
+/-
 Mice. (a) Genotyping profile showed the 
establishment of the double-knockout (DK) mouse line, Rnd3
+/-ROCK1-/-
. (b) Cardiac 
functions of Rnd3
+/- 
mice and DK mice before and after TAC. (c) Representative images 
for TUNEL staining in cardiac sections from Rnd3
+/- 
mice and DK mice after TAC 
(green). Arrows point at TUNEL positive cells overlapped with nuclei counter-staining 
(blue). Cardiomyocytes were visualized by Phalloidin staining for F-actin (red). (d) Less 
TUNEL positive cardiomyocytes were observed in DK mice compared with Rnd3
+/- 
mice. (e)  Immunoblotting of apoptosis marker full-length Casp3 and active Casp3 in 
Rnd3
+/- 
and DK mouse hearts before and after TAC. (f) Densitometry analysis for active 
Casp3 level normalized by GAPDH. The number in each column represents animal 
numbers in each group. One-way ANOVA followed by Student-Newman-Keuls test was 
used for multiple group comparisons. The P value < 0.05 was considered as significant 
difference. Data are presented as means ± s.d. Scale bar represents 10µm. 
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Figure 11. Continued 
 
 
 
 
Genetic deletion of ROCK1 significantly, however not completely, rescued the impaired 
heart function and apoptosis caused by the Rnd3
 
deficiency. These data suggested that 
ROCK1 only partially contributed to the Rnd3 mediated cardiac apoptosis. The ROCK1 
independent mechanism is interesting and worthy to be investigated. Furthermore, in the 
Rnd3
+/- 
mice heart failure model, the responsive angiogenesis defect could be another 
factor contributing to the cardiac dysfunction. Therefore my next study was focused on 
its underlying mechanism. 
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Key Pro-angiogenic Factors, HIF1α and VEGFA were Down-regulated in the 
Rnd3
+/-
 Heart in Response to Pressure Overload 
Besides the cardiac apoptosis, the responsive angiogenesis is another vital factor in the 
chronic heart remodeling and the heart failure development. Hypoxia-inducible factor 1 
(HIF1)-vascular endothelial growth factor A (VEGFA) is one of the most important 
pathways promoting angiogenesis. In heart, cardiomyocyte is the major resource of 
VEGFA. VEGFA directly promotes endothelial cell proliferation, migration and 
increases vascular permeability in the angiogenesis process. The regulation of VEGFA is 
majorly at the transcriptional level by the transcription factors HIF1 and peroxisome 
proliferator-activated receptor-gamma coactivator (PGC)-1α. In order to investigate the 
mechanism underlying the responsive angiogenesis defect in the post-TAC Rnd3
+/- 
heart, 
the expression levels of these angiogenic factors in heart were detected.  
 
The HIF1-VEGFA signaling pathway was detected in the WT and Rnd3
+/- 
hearts. The 
VEGFA protein level as well as the mRNA level was significant decreased in the 
Rnd3
+/- 
heart after TAC compared with the WT control (Figure 12a, b). Along with the 
decreased VEGFA expression, HIF1α, the regulator of VEGFA, was also found down-
regulated in Rnd3
+/- 
heart (Figure 12a). To investigate the effect of Rnd3 on the crosstalk 
between the cardiomyocyte and the endothelium, a tube formation assay was performed. 
The primary WT and Rnd3
+/- 
cardiomyocytes were isolated from post-TAC hearts, and 
then the conditional medium was applied on the human umbilical vein endothelial cells 
(HUVECs) to induce tube formation. After 6 hours the HUVECs developed mature tube 
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structure in the conditional medium. In the conditional medium from Rnd3
+/- 
cardiomyocytes, the HUVECs displayed lower angiogenesis ability compared with the 
WT group, with the less branching points and less loop formations (Figure 12c, d). This 
experiment indicated that compared with the WT conditional medium, the Rnd3
+/- 
conditional medium contained low level angiogenic factors. In order to dissect out which 
angiogenic factor plays more important role in this HUVECs tube formation assay, I 
detected the conditional medium, and found that the Rnd3
+/- 
cardiomyocytes released 
less VEGFA into the medium compared with the WT control (Figure 12e). 
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Figure 12. HIF1-VEGFA Axis was Down-Regulated in the Rnd3
+/- 
Heart after TAC. (a) 
Down-regulation of VEGFA and HIF1α protein levels were observed in Rnd3+/- heart 
tissue. (b) mRNA levels of VEGFA in WT and Rnd3
+/-
 hearts were detected with or 
without TAC surgery stress. Significant decrease was observed in Rnd3
+/-
 hearts. (c) 
Representative images of HUVECs tube formation assay induced by the conditional 
media from WT and Rnd3
+/- 
cardiomyocytes. Fewer tubes were formed in the media 
from Rnd3
+/-
 cardiomyocytes compared with WT control. Scale bar represents 200µm. 
(d) Quantification of HUVECs tube formation analyzed by Wimtube software. Fewer 
branching points and loops were detected in Rnd3
+/- 
group. (e) Decreased secretion of 
VEGFA from Rnd3
+/- 
cardiomyocytes into media was detected. The number in each 
column represents animal numbers in each group. One-way ANOVA followed by 
Student-Newman-Keuls test was used for multiple group comparisons. The p value < 
0.05 was considered as significant difference. Data are presented as means ± s.d. 
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The reduction of VEGFA expression in Rnd3
+/- 
heart tissue after surgery is consistent 
with the failed responsive angiogenesis in Rnd3
+/- 
heart. As the major source of VEGFA, 
the cardiomyocyte affects the proliferation and migration of the endothelial cell in a 
paracrine manner. In response to stress stimulus, Rnd3 deficiency resulted in a decline of 
VEGFA produced from the cardiomyocyte, consequently leaded to the angiogenesis 
defect in heart. HIF1α, the major regulator of VEGFA, was found down-regulated in 
Rnd3
+/- 
heart suggesting a potential mechanism that Rnd3 regulated angiogenesis by 
modulating HIF1α pathway. 
 
Rnd3 Stabilized HIF1α through Physical Interaction  
The regulation of HIF1α depends on oxygen sensitive post-translational modification. 
Under normoxia condition, HIF1α is hydroxylated by the enzyme prolyl hydroxylases 
(PHDs) and subsequently degraded by the ubiquitin-proteasome system (UPS). While 
under hypoxia condition, the activity of PHDs is blocked resulting in the stabilization of 
HIF1α. The accumulated HIF1α translocates into the nucleus and initiates the 
transcriptions of downstream target genes. To explore the mechanism underlying the 
down-regulation of the HIF1α-VEGFA pathway in Rnd3+/- heart, I performed a series of 
gain-loss function experiments manipulating the Rnd3 expression in Hela cell line. 
 
HIF1α protein disappeared when Rnd3 was knocked down (Figure 13a), and 
accumulated gradually along with the Rnd3 overexpression in a dose-dependent manner 
(Figure 13b). When cells overexpressed Rnd3, the accumulation of endogenous HIF1α 
in nuclei was observed by immunostaining (Figure 13c). Consistent with the changes in 
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HIF1α protein levels, the expression of VEGFA was changed in the same pattern (Figure 
13a, b). To further investigate the potential mechanism of Rnd3 induced HIF1α protein 
stabilization, I conducted an in vitro GST-Rnd3 pull-down experiment with the lysate 
from the cells overexpressing HA-HIF1α. The physical binding of GST-Rnd3 with HA-
HIF1α was detected (Figure 13d). A further mutual co-immunoprecipitation assay was 
performed with the lysate from the cells transiently overexpressing Myc-Rnd3 and HA-
HIF1α, the two proteins physically interacting with each other in vivo was observed 
(Figure 13e). Given that HIF1α functions as a transcription factor, I performed a 
luciferase assay to study whether Rnd3 regulated HIF1α transcriptional activity. A 
VEGFA promoter containing three repeats of HIF1 response elements (HRE) was cloned 
into luciferase reporter. Hypoxia treatment was applied to trigger HIF1α expression. 
Initiated by hypoxia condition, Rnd3 knock-down resulted in a 47% reduction in the 
HIF1α transcriptional activity compared with the WT control (Figure 13f). Consistent 
with the decreased HIF1α activity in Rnd3 deficient cell, VEGFA mRNA level 
decreased responsively (Figure 13g). Taken together, Rnd3 directly bound to and 
facilitated the HIF1α protein accumulation. Rnd3 deficiency weakened the transcription 
activity of HIF1α and the expression of its downstream target genes VEGFA.  
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Figure 13. Rnd3 Physically Interacted with HIF1α and Facilitated Its Stability. (a) 
Significant decreases in HIF1α and VEGFA protein levels were detected in cells 
knocked down Rnd3. (b) The protein levels of HIF1α and VEGFA gradually increased 
along with Rnd3 over expression in cells. (c) Representative images displayed that 
HIF1α accumulated in nuclei when cells overexpressing Rnd3. Scale bar represents 
50µm. (d) HA-HIF1α was pull-downed by GST-Rnd3 in vitro. (e) Myc-Rnd3 and HA-
HIF1α physically interacted in the in vivo mutual co-immunoprecipitation experiments. 
(f) Rnd3 knock-down restrained the HIF1α transcription activity evidenced by luciferase 
assay. (g) The Q-PCR result showed that Rnd3 deficiency resulted in VEGFA losing 
response to hypoxia. Unpaired, two-tailed student’s t test was used for two group 
comparisons. The p value < 0.05 was considered as significant difference. Data are 
presented as means ± s.d. 
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Cobalt Chloride, a HIF1α Stabilizer, Partially Attenuated Rnd3 Deficiency 
Mediated Dilated Cardiomyopathy  
Given that the HIF1α-VEGFA pathway was suppressed in the Rnd3+/- heart, and that 
Rnd3 stabilized HIF1α and regulated its transcriptional activity in Hela cells, I 
hypothesized that the responsive angiogenesis defect in Rnd3
+/- 
heart was probably due 
to Rnd3 deficiency induced HIF1α hyper-degradation. To test this hypothesis, I applied a 
HIF1α stabilizer on the Rnd3+/- mice and measured its effects on cardiac function and 
remodeling after TAC. 
 
Cobalt chloride (CoCl2) acts as an inhibitor of prolyl hydroxylases (PHDs), which 
hydroxylates HIF1α and consequently results in the degradation of HIF1α. The 
application of CoCl2 stabilizes HIF1α protein and leads to its accumulation. WT and 
Rnd3
+/- 
mice were exposed to TAC stress with CoCl2 treatments for 3 weeks. After the 
administration of CoCl2, significant improved heart function was observed in Rnd3
+/- 
mice after TAC, with a 61% increase in ejection fraction (EF) and a 68% increase in 
fraction shortening (FS) (Figure 14a). The dilated left ventricle chamber and thin 
ventricular wall caused by TAC stress in Rnd3
+/- 
heart were ameliorated by CoCl2, 
evidenced by H&E staining (Figure 14b) and echocardiography analysis (Figure 14d). In 
post-TAC Rnd3
+/- 
mice, the average ratio of lung weight (LW) over body weight (BW) 
decreased from 19.6 (none-treatment group) to 7.9 (treatment group), and the average 
ratio of LW over tibia length (TL) decreased from 24.8 (none-treatment group) to 13.3 
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(treatment group) (Figure 14c), demonstrating the rescued lung edema which were 
caused by severe heart failure. 
  
To summarize the rescue experiments on Rnd3
+/- 
mouse model, CoCl2 significantly 
improved cardiac function and attenuated heart dilation by stabilizing HIF function, 
which suggested that Rnd3 deficiency mediated dilated cardiomyopathy partially 
through HIF1α destabilization. 
 
Cobalt Chloride Improved Responsive Angiogenesis in the Rnd3
+/- 
Hearts by 
Stabilizing HIF1α 
My data indicated that the CoCl2 mediated HIF1α stabilization played a critical role in 
the transition of Rnd3
+/- 
heart to failure. I still have a question that whether the preserved 
Rnd3
+/- heart function benefits from the angiogenesis promoted by HIF1α accumulation? 
To address this question, I checked the HIF1α-VEGFA pathway and the mouse cardiac 
capillary perfusion.  
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Figure 14. Cobalt Chloride Partially Ameliorated Rnd3 Deficiency Mediated Dilated 
Cardiomyopathy. (a) Cardiac function impairment in Rnd3
+/- 
mice induced by TAC was 
partially attenuated after CoCl2 treatment. (b) H&E staining of cardiac sections from WT 
and Rnd3
+/- 
mice after TAC, with and without CoCl2 treatment. Scale bar represents 
1mm. (c) The ratio of lung weight over body weight and lung weight over tibia length 
indicated that CoCl2 prevented heart failure development in Rnd3
+/- 
mice after TAC. (d) 
The LVPWs and LVIDs of the hearts from WT and Rnd3
+/- 
mice with or without CoCl2 
treatment before and after TAC were compared among groups. TAC stress induced 
dilated cardiomyopathy in Rnd3
+/- 
heart was partially rescued by CoCl2. LVPWs: and 
left ventricular posterior wall thickness at systole; LVIDs: left ventricular internal 
dimension at systole. The number in each column represents animal numbers in each 
group. One-way ANOVA followed by Student-Newman-Keuls test was used for 
multiple group comparisons. The p value < 0.05 was considered as significant difference. 
Data are presented as means ± s.d.   
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The HIF1α and VEGFA protein levels were compared in the WT and Rnd3+/- heart 
before and after TAC, with or without CoCl2 treatment. Consistent with the previous 
result, Rnd3
+/- heart displayed the significantly repressed HIF1α signaling after TAC. 
The CoCl2 application stimulated HIF1α protein accumulation dramatically in the 
Rnd3
+/- 
hearts compared with the non-treatment group. Along with the changes in HIF1α, 
significant increases in VEGFA protein levels were detected in the Rnd3
+/- 
hearts with 
CoCl2 treatment (Figure 15a), indicative of the rescued pro-angiogenic signaling 
pathway. To verify that CoCl2 improved the responsive angiogenesis in Rnd3 deficient 
heart, capillary density and circulational perfusion were detected. Again, I observed the 
increased capillary number and area as well as the improved coronary flow reserve in the 
post-TAC Rnd3
+/- 
hearts after CoCl2 treatment, determined by the histological analysis 
and Doppler measured blood flow (Figure 15b to d).  
 
In the animal study, Rnd3 deficiency resulted in heart failure and responsive 
angiogenesis associated with compromised HIF1-VEGFA signaling pathway. CoCl2 
partially rescued the adaptive vascularization in the Rnd3
+/- 
heart via the compensated 
HIF1-VEGFA signaling pathway, therefore partially attenuated the cardiac dysfunction 
and the dilated cardiomyopathy phenotype. Rnd3 is a novel pro-angiogenesis factor that 
can binds to and stabilizes HIF1α protein. This novel discovery may provide a new 
strategy to the clinical therapy for the heart failure patients. 
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Figure 15. Responsive Angiogenesis Defect in the Post-TAC Rnd3
+/- 
Heart was Partially 
Rescued by CoCl2 Treatment. (a) The depressed HIF1α-VEGFA axis in post-TAC 
Rnd3
+/- 
heart was raised by CoCl2 application. (b) Isolectin-B4 stained cardiac capillaries 
(green) in CoCl2 treated WT and Rnd3
+/- 
post-TAC hearts. Nucleuses were visualized by 
blue DAPI staining. (c) Capillary areas and numbers from WT and Rnd3
+/- 
hearts before 
and after surgery with or without
 
CoCl2 treatment were compared among groups. CoCl2 
significantly improved angiogenesis in Rnd3
+/- 
hearts after TAC. (d) The impaired 
coronary flow reserve in Rnd3
+/- 
heart was partially improved with CoCl2 treatment. The 
number in each column represents animal numbers in each group. One-way ANOVA 
followed by Student-Newman-Keuls test was used for multiple group comparisons. The 
p value < 0.05 was considered as significant difference. Data are presented as means ± 
s.d.   
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CHAPTER IV  
CONCLUSIONS AND DISCUSSION 
 
Rnd3, a constitutive active small Rho GTPase, mediates diversified cell stress response, 
such as DNA damage induced by chemotherapeutic agents or UVB exposure
50, 51
. Its 
expression level varies significantly upon cell differentiation during development and 
under stress, suggesting a delicate regulation of Rnd3 signaling is critical in 
pathophysiology
121
. The down-regulation of Rnd3 protein and mRNA levels were 
detected in end stage human failing hearts in my study and previous reports, suggesting 
that Rnd3 might play a role in the transition of the heart to failure. This study, so far, is 
the first one that investigates the role of Rnd3 in regulating heart failure under 
hemodynamic stress. Loss of Rnd3 in mouse myocardium resulted in severe apoptosis 
and impaired responsive angiogenesis induced by TAC compared to wild type 
littermates.  Along with the massive apoptosis, ROCK1 signaling and Caspase3 were 
activated in the myocardium. My data suggested that the activated ROCK1 and 
Caspase3 are at least partially responsible for the cell death. Since ROCK1 inhibitor, 
Fasudil, or genetic deletion of ROCK1 can significantly attenuate the apoptotic 
cardiomyopathy and sequentially recover the heart function. My study further confirmed 
the regulatory effect of Rnd3 on ROCK1 signaling in the heart, and provided a new 
candidate gene for new drug development targeting apoptotic cardiomyopathy. Whereas 
inhibition of ROCK1 could only partially rescue apoptosis and cardiac remodeling, 
suggesting that a ROCK1 independent pathway may exist. My further study investigated 
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the underlying mechanism and found that the compromised HIF1α-VEGFA signaling 
pathway mediated the angiogenesis defect in the Rnd3
+/- 
heart and was responsible for 
the pathological changes. For the first time, my study demonstrated that Rnd3 physically 
binds to HIF1α and stabilizes it in the nucleus, resulting in its downstream angiogenesis 
pathway activation. Administration of cobalt chloride significantly rescued the down-
regulation of HIF1α-VEGFA in the Rnd3+/- heart and attenuated the angiogenesis defect-
mediated heart dysfunction. My study demonstrated a novel regulatory mechanism of 
angiogenesis in the hemodynamic stress exposed heart and provided a new potential 
strategy for therapeutic angiogenesis. 
 
Role of Rnd3 in Apoptosis 
Loss of Rnd3 induced cell death has been studied in different cell types. Rnd3 is a p53 
target gene, and inhibits ROCK1-mediated apoptosis in response to genotoxic stress in 
many cell lines
46
. However, in U87 and keratinocytes, down-regulation of Rnd3 induced 
apoptosis appears more involved in the regulation of the ERK and p38 pro-survival 
pathway
122, 123
, while in prostate cancer cell lines, its effect on cell apoptosis is closely 
associated with cell cycle regulation
124
. Interestingly, as a major event after myocardial 
infarction and many other heart diseases, the role of Rnd3 in cardiomyocyte apoptosis is 
poorly studied. Two major questions need to be answered: Does Rnd3 protect 
cardiomyocytes from apoptosis? How does Rnd3 regulate cardiomyocyte behavior after 
stress? This study showed that loss of Rnd3 triggered stronger apoptotic signaling after 
TAC. Rnd3 deficiency-mediated apoptosis is Rho Kinase dependent partially. 
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Role of Rnd3 in Heart End Stress 
Hemodynamic stress induces significant cardiac remodeling.  Our previous study 
showed that mice with overexpression of truncated ROCK1 are predisposed to 
angiotensin II induced cardiac fibrosis
43
. Since studies have shown that Rnd3 is a 
ROCK1 endogenous inhibitor
45
, loss of Rnd3 should potentiate ROCK1 signaling. 
However, I did not see a significant difference in ROCK1 activity between the WT and 
the heterozygous Rnd3 mice. While under TAC induced stress condition, ROCK1 
activity increased dramatically compared to the WT littermates, suggesting that the 
inhibition of ROCK1 by Rnd3 in heterozygous heart is a stress responsive process. Due 
to the embryonic lethality, further study focusing on the Rnd3 regulatory effect on 
ROCK1 in physiological condition should be conducted by using conditional Rnd3 
knockout mice. It is also one of our on-going projects.  
 
Caspase3 and Rho Kinase Activation in Apoptosis 
ROCK1 has been shown to be closely associated with heart diseases, such as 
hypertension and fibrosis
43, 125, 126, 127
. Our previous study suggested that activation of 
ROCK1 by caspase3 cleavage played an essential role in cardiac apoptosis
42
.  Apoptotic 
signals activated caspase 3, which can cleave ROCK1 resulting in a constitutive active 
ROCK1 isoform. The active ROCK1, on one hand, phosphorylated PTEN, which 
inhibited the pro-survival Akt pathway. On the other hand, the role of ROCK1 in 
apoptosis may be through the regulation of actin assembly to activate programed cell 
death signaling
128, 129, 130
. Specific Rho kinase 1 inhibitor development is still a challenge. 
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Rnd3 can only bind to ROCK1 but not ROCK2, providing a good drug candidate for 
specific targeting of ROCK1 signaling.  My data suggests that the inhibition of ROCK1 
only partially rescued the apoptosis, indicating other signals participate in Rnd3-
mediated apoptosis (Figure 16). Investigation of Rnd3 mediated apoptosis independent 
of ROCK1 becomes interesting. The Rnd3
+/-ROCK1-/-
 mouse line could be a great tool for 
this purpose. Rnd3 expression is dynamically regulated by different stresses, and it is 
also a target gene of p53. These provide the possibility that development of a specific 
compound could regulate Rnd3 expression without any modification of chromosomes. It 
is also possible that we can control patients’ ROCK1 activities by modify Rnd3 
expression with new development of Rnd3 agonists.  
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Figure 16. Mechanisms in the Rnd3 Mediated Heart Failure.  
 
 
 
 
Fasudil and Cardiovascular Disease  
Fasudil, targeting at the ATP-dependent kinase domain, is a commonly used ROCK 
inhibitor
25, 131
. Fasudil was widely used in ROCK study on cardiovascular disease, and 
functions as a vasodilator because of ROCK’s regulation on smooth muscle contractility. 
Animal experiments showed Fasudil prevented ROCK-dependent hypertension
34, 132
, 
atherosclerosis
133, 134
, pulmonary hypertension
135, 136, 137
, stroke
138
 and myocardial 
infarction
139, 140
. In Japan, Fasudil was approved in 1995 for the treatment of cerebral 
vasospasm, which is the only clinical used ROCK inhibitor. Nowadays, the clinical trials 
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of Fasudil’s therapeutical effects on cardiovascular disease, such as coronary artery 
disease
141
, angina
142, 143, 144
, pulmonary arterial hypertension
145, 146, 147
 and stroke
148
, are 
ongoing in different countries
15
.  
 
Although Fasudil reduced blood pressure in many pulmonary arterial hypertension 
models, the application of Fasudil in WT and Rnd3
+/- 
mice did not result in blood 
pressure change. The non-specific inhibitory effects of Fasudil on other serine/ threonine 
kinases, such as PKA and PKC, have been reported at high dosage treatment
15, 149
. To 
minimize any possible side effects of Fasudil and also to verify the ROCK1’s potential 
mechanism in Rnd3-mediated apoptotic cardiomyopathy, I generated the mice with the 
Rnd3 and ROCK1 double knockout background. Consistent with the rescue effects of 
Fasudil on the cardiac phenotype, loss of ROCK1 gene also attenuated apoptotic 
cardiomyopathy partially. The data provided explicit evidence that Rnd3-mediated 
apoptotic cardiomyopathy is partially through a ROCK1-dependent pathway. 
 
Role of Rnd3 in Angiogenesis 
Early studies have reported that impaired cardiac capillary circulation led to heart failure. 
The patients with dilated cardiomyopathy suffered from left ventricle dysfunction 
associated with compromised myocardial perfusion, suggesting that abnormal cardiac 
perfusion plays a vital role in the development of heart to failure
150, 151, 152, 153
. CFR, the 
ratio of coronary flow velocity under stimuli and basal conditions, served as an index of 
coronary microvasculature. Cardiac angiogenesis was stimulated by hemodynamic 
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pressure overload with increased capillary density and CFR as the WT heart showed 
after TAC. However this compensatory response was insufficient in the Rnd3
+/- 
heart 
and consequently resulted in pathological transition. The Rnd3
+/- 
mice recapitulated the 
situations observed in human heart failure patients and is a novel disease-relevant mouse 
model.   
 
Compromised HIF1α-VEGFA Signaling in Ischemic Heart 
HIF1α mediated up-regulation of pro-angiogenic factors are critical in ischemia induced 
adaptive angiogenesis. HIF1α accumulation was detected in human hearts with ischemic 
stress
154
. In the mouse model in response to TAC stress, HIF1α and VEGFA were found 
to be activated within one week, but were decreased during days 14 to 28 along with 
cardiac remodeling and dysfunction. The patterns of HIF1α expression and angiogenesis 
were dynamic in the transition of the heart to failure
155
. Since cardiomyocytes are the 
major resource of VEGFA in the heart, the effect of cardiomyocyte-specific HIF1α on 
angiogenesis was investigated. Knockout of HIF1α in mouse cardiomycytes was proven 
to contribute to baseline poor vasculature and cardiac dysfunction
156
. Cardiac-specific 
knockout of HIF1α from one allele resulted in an angiogenesis defect and cardiac 
contractile dysfunction after TAC
155
. 
 
The Rnd3
+/- 
mouse line is a novel model for angiogenesis study. Under basal condition, 
Rnd3
+/- 
mice developed normal cardiac angiogenesis with similar capillary density, 
coronary flow reserve and HIF1α-VEGFA levels compared with the WT control. Under 
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hemodynamic stress challenge condition, the activated HIF1α-VEGFA pathway was 
detected in the WT heart, whereas failed HIF1α-VEGFA compensation was detected in 
the Rnd3
+/- 
heart, resulting in the failure of adaptive angiogenesis indicated by low 
capillary density and reduced coronary flow reserve. Consistent with the phenotype 
exhibited in Rnd3
+/- 
mice, an endothelial cell tube formation assay using cardiomyocyte 
conditional medium demonstrated that Rnd3
+/- 
cardiomyocytes secreted less VEGFA 
compared with the WT control. The repressed HIF1α-VEGFA signaling is responsible 
for the angiogenesis defect mediated transition of the heart to failure. 
 
Cobalt chloride stabilizes HIF1α by inhibiting PHD157. To verify the HIF1α-VEGFA 
regulatory axis in the Rnd3 deficiency mediated angiogenesis defect, cobalt chloride was 
applied as a mouse heart failure precondition treatment. In the TAC stress exposed 
Rnd3
+/- 
heart, the administration of cobalt chloride stimulated capillary generation, 
improved myocardial perfusion, rescued left ventricle dilation and promoted cardiac 
function. The compromised HIF1α-VEGFA pathway in the Rnd3+/- heart was also 
rescued by cobalt chloride application. Interestingly, although cobalt chloride has an 
effect on WT and Rnd3
+/- mice and stimulated HIF1α accumulation, the WT heart 
exhibited much higher levels of HIF1α compared with the mutant heart. The VEGFA 
levels were greatly induced, however, did not show significant difference between the 
two groups after cobalt chloride treatment. This situation indicated that stabilization of 
HIF1α promoted VEGFA mediated angiogenesis and rescued dilated cardiomyopathy in 
the Rnd3 deficient heart, whereas high doses of HIF1α probably cannot further push the 
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VEGFA expression, which suggests other potential mechanisms regulating the VEGFA 
pathway. 
 
Rnd3-HIF1α Regulation Loop 
HIF1α is a ubiquitously expressed oxygen sensor protein. In normoxia, HIF1α stays in 
the cytoplasm and is degraded by 26S proteasome after binding with ubiquitin E3 ligase 
VHL. The in vivo data showed that HIF1α protein levels decreased in the Rnd3 mutant 
heart after TAC stimuli, and our loss- and gain-of-function experiments further 
demonstrated that Rnd3 facilitated HIF1α protein accumulation in the nucleus, 
suggesting that Rnd3 plays a regulatory role in HIF1α protein turnover. An 
immunoprecipitation experiment demonstrated that Rnd3 physically bound to HIF1α 
protein. Therefore, I proposed a novel angiogenesis regulatory mechanism that Rnd3 
binds to and stabilizes HIF1α and consequently enhances the VEGFA mediated 
angiogenesis pathway (Figure 17). On the other hand, Rnd3 probably is regulated by 
HIF1α at the transcriptional level as a feedback regulation loop. HIF1α was found to 
interact with the HRE element in the Rnd3 gene promoter region during hypoxia, and 
was associated with the up-regulation of Rnd3 in response to hypoxia stimuli
158
. Given 
the vital role of HIF1α in angiogenesis, Rnd3 may function as a new positive regulator 
and activation of Rnd3 may be an attractive option in therapeutic angiogenesis.  
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Figure 17. Proposed Model of the Molecular Mechanism of Rnd3 in Angiogenesis. Rnd3 
interacts and stabilizes HIF1α facilitating the activation of VEGF transcription in nuclei. 
The HIF1α monomer is quickly degraded by UPS system after the hydroxylation 
modification by enzyme PHD under normoxia condition. The hydroxylation can be 
blocked by cobalt chloride. UPS: ubiquitin-proteasome system; PHD: prolyl hydroxylase 
domain. 
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